Development of Small Molecules as Chemical Tools for Investigating the Role of Metal-Protein Interactions in Neurodegenerative Diseases. by Beck, Michael William
 
 
Development of Small Molecules as Chemical Tools for Investigating the Role of 
Metal−Protein Interactions in Neurodegenerative Diseases 
 
by 
 
Michael William Beck 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of  
Doctor of Philosophy 
(Chemistry) 
in The University of Michigan 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
 Associate Professor Mi Hee Lim, Co-Chair 
 Associate Professor Nicolai Lehnert, Co-Chair 
 Professor Ayyalusamy Ramamoorthy 
Assistant Professor Brandon T. Ruotolo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Michael William Beck 
2015 
 
  ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To all those who are afflicted by neurodegenerative diseases. 
  
  iii 
 
Acknowledgements 
 
First and foremost, I am eternally grateful to my PhD advisor Professor Mi Hee 
Lim. Without her guidance, encouragement, patience, and assistance this dissertation 
would never have been completed. She has always been supportive of my ideas and 
willing to discuss my results or other scientific topics. Additionally, I want to thank her for 
the unique opportunity to spend a year at Ulsan National Institute of Science and 
Technology (UNIST) in the Republic of Korea to continue to work in her laboratory. 
I would like to also thank my dissertation committee members: Professors Nicolai 
Lehnert, Brandon Ruotolo, and Ayyalusamy Ramamoorthy for their insights and 
critiques during our meetings which have made me a better scientist. I would like to 
particularly thank Professor Lehnert for agreeing to be a co-chair for my dissertation 
committee due to the transition of Professor Lim to UNIST. Additionally, I want to 
express my gratitude for all of my teachers and professors throughout my life especially 
Professor Ed Lisic, my undergraduate research advisor, who gave me my first research 
opportunity and encouraged me to continue with my studies at the graduate level, as 
well as, my internship mentors at Colgate-Palmolive, Dr. Ryan Cameron and Debbie 
Peru for their guidance and helpful advice.  
 I want to also express my sincere appreciation for the people who I have 
collaborated with during the course of my PhD studies who are recognized for their 
contributions to this thesis at the beginning of each chapter. I also want to thank all of 
my Lim group labmates both past and present for their assistance, mentorship, scientific 
discussion, and friendship, particularly the following members who have been especially 
influential: Dr. Xiaoming He, Dr. Joey Braymer, Dr. Alaina DeToma, Dr. Akiko Kochi, Dr. 
Masha Savelieff, Amit Pithadia, Hyuck Jin Lee, Kyle Korshavn, Younwoo Nam, Juhye 
Kang, Jeffrey Derrick, and Jeeyeon Lee. I would also like to acknowledge those who, in 
addition to Professor Lim, helped me with living in Korea most importantly Mi Sook Lim 
who made sure that I had everything in order to travel to Korea, assisted me in getting 
  iv 
set up there, and made sure everything else during my stay was in order, and Hyuck Jin 
Lee who helped me with everything else, as well as Dr. Yeon Ju Kwak, Younwoo Nam, 
Milim Jang, Juhye Kang, Jin Hoon Kim, Jung Ha Lee, Jeeyeon Lee, Yonghwan Ji, 
Eunju Nam, and Jiyeon Han.  
I would also like to thank all of my friends and family for their support during the 
course of my PhD studies. 
To my sister, for putting up with me while growing up and taking care of things 
while I have been unable to help out at home.  
 To my wonderful girlfriend, Emily, thank you for being so understanding and all of 
your encouragement and reassurance.  
Last, but certainly not least, to my parents, Scott and Mary Beck, despite their 
constant reminders that “I can always quit and come live at home,” I appreciate 
everything they have done to ensure that I could receive a good education and to be 
able to follow my dreams. I also want to thank them for putting up with and feeding me 
while I wrote this dissertation. 
  
  v 
 
Table of Contents 
Dedication ......................................................................................................................... ii	  
Acknowledgements ......................................................................................................... iii	  
List of Tables ................................................................................................................... ix	  
List of Figures ................................................................................................................... x	  
List of Appendices ......................................................................................................... xxi	  
List of Abbreviations ..................................................................................................... xxiii	  
Abstract ...................................................................................................................... xxviii	  
Chapter 1: Ligand design to target and modulate metal-protein interactions in 
neurodegenerative diseases ............................................................................................ 1	  
1.1.	   Introduction .......................................................................................................... 2	  
1.1.1. Metals in the brain ........................................................................................... 2	  
1.1.2. Aberrant metal–protein interactions ................................................................ 4	  
1.1.3. Oxidative stress ............................................................................................... 5	  
1.2. Alzheimer’s disease (AD) ....................................................................................... 6	  
1.3. Ligand design to target and modulate metal−protein interactions ......................... 7	  
1.3.1. Metal chelating compounds ........................................................................... 11	  
1.3.2. Small molecules designed for metal−protein complexes .............................. 14	  
1.3.3. Other relevant compounds ............................................................................ 18	  
1.3.4. Naturally occurring molecules ....................................................................... 20	  
1.4. Methods to study the ability of small molecules to mediate the aberrant 
interaction of metal ions and proteins ......................................................................... 21	  
1.4.1. Techniques for determining blood brain barrier permeability ........................ 22	  
1.4.2. Strategies for studying the interaction of compounds with metal ions, 
proteins, and metal−protein complexes ................................................................... 23	  
1.4.3. Systems for exploring the metal-induced protein aggregation ...................... 25	  
1.4.4. Approaches for studying the ability of compounds to mediate oxidative stress
 ................................................................................................................................ 27	  
1.4.5. Experiments for determining the ability to relieve metal-protein complex 
cytotoxicity ............................................................................................................... 28	  
1.5. Conclusions ......................................................................................................... 28	  
1.6. Scope of thesis .................................................................................................... 29	  
1.7. References ........................................................................................................... 31	  
Chapter 2: A rationally designed small molecule for identifying an in vivo link between 
metal-amyloid-β complexes and the pathogenesis of Alzheimer's disease .................... 40	  
2.1. Introduction .......................................................................................................... 41	  
2.2. Results and discussion ........................................................................................ 42	  
  vi 
2.2.1. Design principle and characterization of a chemical tool for investigating 
metal−Aβ complexes in vivo .................................................................................... 42	  
2.2.2. Specific modulation of metal-induced over metal-free Aβ aggregation 
pathways in vitro ...................................................................................................... 45	  
2.2.3. Formation of structurally-compact complexes with metal−Aβ not metal-free 
Aβ in vitro ................................................................................................................ 47	  
2.2.4. Targeting and reacting with metal−Aβ complexes in living cells and in the 
brain of 5XFAD AD mice ......................................................................................... 51	  
2.2.5. Reduction of amyloid pathology in 5XFAD AD mice ..................................... 52	  
2.2.6. Cognitive improvement in 5XFAD AD mice ................................................... 55	  
2.3. Conclusions ......................................................................................................... 57	  
2.4. Experimental section ............................................................................................ 57	  
2.4.1. Materials and methods .................................................................................. 57	  
2.4.2. Aβ aggregation experiments ......................................................................... 58	  
2.4.3. Gel electrophoresis and Western blotting ..................................................... 58	  
2.4.4. Dot blot analysis ............................................................................................ 59	  
2.4.5. Transmission electron microscopy (TEM) ..................................................... 59	  
2.4.6. Ion mobility–mass spectrometry (IM–MS) ..................................................... 59	  
2.4.7. Cell viability measurements ........................................................................... 60	  
2.4.8. Antioxidant assay .......................................................................................... 61	  
2.4.9. Brain uptake studies ...................................................................................... 62	  
2.4.10. Metabolic stability ........................................................................................ 62	  
2.4.11. Animals and drug administration ................................................................. 63	  
2.4.12. Tissue preparation ....................................................................................... 63	  
2.4.13. Measurement of synaptic Zn(II) ................................................................... 63	  
2.4.14. Aβ40/Aβ42 quantification ............................................................................... 64	  
2.4.15. Quantification of Aβ deposition .................................................................... 64	  
2.4.16. Immunoblot analysis of Aβ .......................................................................... 65	  
2.4.17. Behavioral evaluation .................................................................................. 65	  
2.4.18. Statistics ...................................................................................................... 66	  
2.5. Acknowledgements .............................................................................................. 66	  
2.6. References and notes .......................................................................................... 67	  
Chapter 3: Structural similarity of small molecules, but distinct targets and reactivities in 
amyloidogenic diseases through multiple modes of action ............................................ 69	  
3.1. Introduction .......................................................................................................... 70	  
3.2. Results and discussion ........................................................................................ 71	  
3.2.1. Rational selection of small molecules and the model peptide system .......... 71	  
3.2.2. Reactivity I: Modulation of metal-free and metal-induced peptide aggregation 
by 1-4 ...................................................................................................................... 76	  
3.2.3. Reactivity II: Mediation of oxidative stress by 1-4 ......................................... 78	  
3.2.4. Reactivity III: Regulation of metal-free and metal-treated peptide toxicity by 1-
4 .............................................................................................................................. 79	  
3.2.5. Mechanistic studies I: Solution species in the absence and presence of Cu(II)
 ................................................................................................................................ 80	  
3.2.6. Mechanistic studies III: Computational studies ............................................. 84	  
  vii 
3.2.7. Proposed modes of action of 1-4 toward metal-free and metal-peptide 
reactivity .................................................................................................................. 86	  
3.3. Concluding remarks ............................................................................................. 87	  
3.4. Experimental section ............................................................................................ 87	  
3.4.1. Materials and methods .................................................................................. 87	  
3.4.2. Preparation of 4-nitro-N-(pyridin-2-ylmethyl)aniline ....................................... 88	  
3.4.3. Preparation of 1 ............................................................................................. 88	  
3.4.4. Preparation of 2 ............................................................................................. 89	  
3.4.5. Preparation of 3 ............................................................................................. 89	  
3.4.6. Preparation of 4 ............................................................................................. 90	  
3.4.7. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) .............................................................................................. 90	  
3.4.8. Aβ aggregation experiments ......................................................................... 90	  
3.4.9. Gel electrophoresis and Western blotting ..................................................... 91	  
3.4.10. Transmission electron microscopy (TEM) ................................................... 92	  
3.5.11. Cell viability studies ..................................................................................... 92	  
3.4.12. Primary neuron cultures .............................................................................. 92	  
3.4.13. Antioxidant assay ........................................................................................ 93	  
3.4.14. 2-Deoxyribose assay ................................................................................... 93	  
3.4.15. Determination of solution speciation for 1, 2, 3, and Cu(II)–3 complex ....... 94	  
3.4.16. Stability studies ........................................................................................... 94	  
3.4.17. Calculation of transition state energies and ionization potentials ................ 95	  
3.5. Acknowledgements .............................................................................................. 95	  
3.6. References ........................................................................................................... 96	  
Chapter 4: Utilizing divergent pathways of activities to mediate multiple features in 
Alzheimer’s disease ........................................................................................................ 99	  
4.1. Introduction ........................................................................................................ 100	  
4.2. Results and discussion ...................................................................................... 102	  
4.2.1. Design principles for a chemical library ....................................................... 103	  
4.2.2. Modulation of metal-free Aβ and metal−Aβ aggregation ............................. 106	  
4.2.3. Proposed mode of action (I) for modulation of metal-free Aβ reactivity ...... 109	  
4.2.4. Proposed mode of action (II) for control of Cu(II)−Aβ reactivity .................. 112	  
4.2.5. Proposed mode of action (III) for modulation of Zn(II)−Aβ reactivity ........... 118	  
4.2.6. Exploration of structural features required for interacting with fibrils of Metal-
free Aβ and Zn(II)−Aβ ............................................................................................ 121	  
4.2.7. Mediation of oxidative stress ....................................................................... 124	  
4.2.8. Regulation of toxicity induced by metal-free and metal-associated Aβ ....... 125	  
4.3. Conclusions ....................................................................................................... 125	  
4.4.1. Materials and methods ................................................................................ 126	  
4.4.2. Preparation of 1-4, 6, and L2-b ................................................................... 127	  
4.4.3. Preparation of 5 ........................................................................................... 127	  
4.4.4. Preparation of 7 ........................................................................................... 127	  
4.4.5. Preparation of 8 ........................................................................................... 127	  
4.4.6. Preparation of 9 ........................................................................................... 128	  
4.4.7. Calculation of ionization potentials .............................................................. 128	  
  viii 
4.4.8. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) ............................................................................................ 128	  
4.4.9. Aβ aggregation experiments ....................................................................... 128	  
4.4.10. Gel electrophoresis and Western blotting ................................................. 129	  
4.4.11. Transmission electron microscopy (TEM) ................................................. 130	  
4.4.12. Determination of solution speciation for 5-8 and Zn(II)–1 complex ........... 130	  
4.4.13. Stability studies ......................................................................................... 130	  
4.4.14. 2D NMR spectroscopy .............................................................................. 131	  
4.4.15. Saturation transfer difference (STD) NMR spectroscopy .......................... 131	  
4.4.16. Antioxidant assay ...................................................................................... 132	  
4.4.17. 2-Deoxyribose assay ................................................................................. 132	  
4.4.18. Cell viability studies ................................................................................... 132	  
4.5. Acknowledgements ............................................................................................ 133 
4.6. References ......................................................................................................... 134	  
 
Chapter 5: Concluding remarks and perspective ........................................................ 137 
References ............................................................................................................ 140	  
 
Appendices ................................................................................................................... 141	  
 
  
  ix 
 
List of Tables 
 
Table 1.1. Metal ions in the brain ..................................................................................... 2	  
Table 1.2. Amino acid residues and binding affinities for metal−protein complexes 
involved in AD ................................................................................................................... 8	  
Table 2.1. Distribution of L2-b in male CD1 mice after its administration by oral gavage.
 ........................................................................................................................................ 44	  
Table 2.2. Calculated collision cross section (CCS) values* of the 4+ species of Aβ40. 49	  
Table 2.3. Changes in body weight in nontransgenic littermates and 5XFAD mice during 
the period of vehicle or L2-b treatment. ......................................................................... 54	  
Table 3.1. Calculated and measured BBB permeability parameters for 1-4. ................. 72	  
Table 3.2. Rate of transformation and half-lives of 1-4 in the presence and absence of 
Cu(II). .............................................................................................................................. 81	  
Table 4.1. The first and second ionization potentials for 5-9 and L2-b. ....................... 103	  
Table 4.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and logPe) of 5-9. ................ 104	  
Table A.1. Calculated and measured BBB permeability parameters for L3-b. ............ 143	  
Table B.1. Calculated and measured BBB permeability parameters for the cLick2 
series. ........................................................................................................................... 159	  
 
  
  x 
 
List of Figures 
 
Figure 1.1. Selected metals and proteins involved in the pathogenesis of 
neurodegenerative diseases. Alzheimer’s disease (AD; Cu, Zn, and Fe; amyloid-β (Aβ) 
(PDB 2LFM)30), amyotrophic lateral sclerosis (ALS; Cu and Zn; superoxide dismutase 
(SOD) (PDB 1SPD)31), Parkinson’s disease (PD; Fe and Zn; α-synuclein (α-syn) (PDB 
2KKW)32), Huntington’s disease (HD; Cu and Fe; huntingtin (htt) (PDB 4FED)33), and 
prion disease (Mn, Cu, and Zn; prion protein (PrP) (PDB 1QLX)34). ................................ 4	  
Figure 1.2. Fenton reaction and Haber-Weiss cycle for the catalytic production of ROS 
by Fe(II/III). Similar redox chemistry occurs for Cu(I/II). .................................................... 6	  
Figure 1.3. Structures of selected metal chelators. EDTA, 2,2’,2’’,2’’’-(ethane-1,2-
diylbis(azanetriyl))tetraacetic acid; DFP, 3-hydroxy-1-methylpyridin-4(1H)-one; 8-HQ, 8-
hydroxyquinoline; DFO, N’-{5-[acetyl(hydroxy)-amino]pentyl}-N-[5-({4-[(5-
aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino )pentyl]-N-hydroxysuccinamide); 
phen, 1,10-phenanthroline; D-penicillamine, (S)-2-amino-3-mercapto-3-methylbutanoic 
acid. .................................................................................................................................. 9	  
Figure 1.4. 8-Hydroxyquinoline (8-HQ) derivatives previously utilized in clinical trials for 
treating AD. CQ, 5-chloro-7-iodoquinolin-8-ol; PBT-2, 5,7-dicholoro-2-
[(dimethylamino)methyl]quinolin-8-ol. ............................................................................. 13	  
Figure 1.5. Structures of thioflavin-T (ThT) derivatives. ThT, 4-(3,6-
dimethylbenzothiazol-3-ium-2-yl)-N,N-dimethylaniline; XH1, ([(4-(benzothiazol-2-
yl)phenylcarbamoyl)methyl]-{2-[(2-{[(4-(benzothiazol-2-
yl)phenylcarbamoyl)methyl](carboxymethyl)amino}ethyl)(carboxymethyl)amino] 
ethyl}amino)acetic acid; FC1, N,N-bis(pyridin-2-ylmethyl)-3a,7a-dihydrobenzothiazol-2-
amine; L1, 4-(3a,7a-dihydrobenzothiazol-2-yl)-2-methoxy-6-((methyl(pyridin-2-
ylmethyl)amino)methyl)phenol; L2, 2-((bis(pyridin-2-ylmethyl)amino)methyl)-4-(3a,7a-
dihydrobenzothiazol-2-yl)-6-methoxyphenol; HBTI, 2-(benzothiazol-2-yl)-4-iodophenol; 
HBXI, 2-(benzoxazol-2-yl)-4-iodophenol; and BMI, 2-(1H-benzimidazol-2-yl)-4-
iodoaniline. ..................................................................................................................... 15	  
Figure 1.6. Structures of small molecules designed based on the frameworks of (a) the 
stilbene derivative, (4-(dimethylamino)-4’-iodostilbene); (b) IMPY, ((2-(4’-
dimethylaminophenyl)-6-iodoimidazo[1,2-a]pyridine)); and (c) diphenylpropynone, (3-(4-
(dimethylamino)phenyl)-1-(4-iodophenyl)-2-propyn-1-one. L1-b, N1,N1-dimethyl-N4-
(pyridin-2-ylmethylene)benzene-1,4-diamine; L2-b, N1,N1-dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine; K0, 2-[4-(dimethylamino)phenyl]imidazo[1,2-a]pyridin-8-
ol; K2, 6-(6-iodoimidazo[1,2-a]pyridin-2-yl)-N,N-dimethylpyridin-3-amine; DPP2, 3-(4-
(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-yn-1-one; C2, (E)-3-(4-
(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-en-1-one; P2, 3-(4-
  xi 
(dimethylamino)phenyl)-1-(pyridin-2-yl)propan-1-one; PA2, N-(4-(dimethylamino)phenyl) 
picolinamide. ................................................................................................................... 17	  
Figure 1.7. Structures of pyridine- and cyclen-based ligands. ENDIP, N1,N2-bis(pyridin-
2-ylmethyl)ethane-1,2-diamine; L1’, 4-(2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-
yl)ethyl)morpholine; and cyc-curcumin, 4-((1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-
dioxohepta-1,6-dienyl)-2-methoxyphenyl (2-(1,4,7,10-tetraazacyclododecan-1-
yl)acetyl)glycinate. .......................................................................................................... 19	  
Figure 1.8. Structures of selected, naturally occurring compounds. Myricetin, 3,5,7-
trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone; EGCG, [(2R,3R)-5,7-dihydroxy-2-
(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; resveratrol, 3,4’,5-
trihydroxy-trans-stilbene; curcumin, (1E,6E)-1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione. ..................................................................................................... 20	  
Figure 1.9. Illustration of the ‘sandwiched’ wells of the PAMPA-BBB assay. Compound 
in the donor well diffuses across a lipid membrane in the acceptor well. After a set 
amount of time the concentration of the compound in both wells is determined and used 
to calculate its permeability value (logPe). ...................................................................... 22	  
Figure 1.10. Schematic representation of the basic principles of STD NMR. The protein 
is selectively magnetically saturated (represented by orange color) and the saturation is 
then transferred to the bound ligand. The disassociation of the saturated ligand before 
relaxation gives rise to the STD signal, which is proportional in intensity to the previous 
proximity of ligand atoms to the protein. ......................................................................... 24	  
Figure 1.11. Schemes of the mechanisms of antioxidant assays. (a) The ABTS assay 
depends on the quenching of the ABTS cationic radical (ABTS+•) by a single electron 
transfer from the compound (Cmpd) being studied. ABTS = 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid. (b) In the deoxyribose assay, I. reduced redox 
active metal ions (Mn-1) oxidize in the presence of hydrogen peroxide (H2O2) to produce 
hydroxyl molecules and hydroxyl radicals. II. Hydroxyl radicals then react with and 
degrade 2-deoxyribose to form malonaldehyde in six steps. III. After a set time interval, 
excess thiobarbituric acid is added and reacted with the malonaldehyde formed in the 
previous step producing a chromogen with a strong absorbance at ca. 530 nm and 
water. .............................................................................................................................. 26	  
Figure 1.12. Scheme of MTT reduction in living cells exploited by the MTT assay. MTT 
is reduced by an NADPH-dependent cellular reductase to produce the highly colored 
MTT Formazan. MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; MTT 
Formazan = 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan. ................................... 28	  
Figure 2.1. Design principle of L2-b and its effect on metal-free and metal-induced Aβ 
aggregation. (a) Design principle of L2-b, a metamorphosizer for metal–Aβ complexes: 
a metal binding site (orange) is incorporated into an Aβ interacting framework (blue). (b) 
Scheme showing the inhibition experiment: metal-free or metal-treated [CuCl2 (blue) or 
ZnCl2 (green)] Aβ40/Aβ42 was incubated with (+) or without (−) L2-b for 4 h (left) and 24 
h (right). Conditions: [Aβ] = 25 µM; [Cu(II) or Zn(II)] = 25 µM; [L2-b] = 50 µM; pH 6.6 (for 
Cu(II) samples) or pH 7.4 (for metal-free and Zn(II) samples); 37 °C; constant agitation. 
(c) Analysis of the size distribution of the resultant Aβ42 species by gel electrophoresis 
  xii 
and Western blotting with an anti-Aβ antibody (6E10). (d) Dot blot analysis of the 
resulting Aβ42 species employing 6E10, an anti-Aβ oligomer antibody (A11), and an anti-
Aβ fibril antibody (OC). (e) TEM images of the 24 h incubated samples (scale bar = 200 
nm). ................................................................................................................................ 43	  
Figure 2.2. Effect of L2-b on preformed aggregates of Aβ40 and Aβ42. (a) Scheme of the 
disaggregation experiment: Aβ40 (left) or Aβ42 (right) aggregates, generated by 24 h 
incubation of peptides with and without CuCl2 (blue) or ZnCl2 (green), were treated with 
L2-b (+) followed by an additional incubation of 4 h or 24 h. Conditions: [Aβ] = 25 µM; 
[Cu(II) or Zn(II)] = 25 µM; [L2-b] = 50 µM; pH 6.6 (for CuCl2 samples) or pH 7.4 (for 
metal-free and Zn(II) samples); 37 °C; constant agitation. (b) Analysis of the size 
distribution of the resultant Aβ species by gel electrophoresis and Western blotting with 
an anti-Aβ antibody (6E10). (c) TEM images of the 24 h incubated samples (scale bar = 
200 nm). ......................................................................................................................... 45	  
Figure 2.3. Effect of L2-b on the formation of metal-free and metal-induced Aβ40 
aggregation (inhibition experiment). The experimental conditions are described in Figure 
2.1b. (a) Analyses of the size distribution of the resultant Aβ40 species by gel 
electrophoresis and Western blotting with an anti-Aβ antibody (6E10). (b) Dot blot 
analysis of the resulting Aβ40 species employing 6E10, an anti-Aβ oligomer antibody 
(A11), and an anti-Aβ fibril antibody (OC). (c) TEM images of the 24 h incubated 
samples (scale bar = 200 nm). ....................................................................................... 46	  
Figure 2.4. Mass spectrometric (MS) and ion mobility-mass spectrometric (IM-MS) 
analyses of Aβ in the presence of L2-b and/or Cu(II). (a) Comparison of incubated Aβ 
4+ charge states in the samples containing (i) Aβ40 (18 µM) alone and Aβ40 co-
incubated with (ii) excess L2-b (120 µM), (iii) Cu(II) (40 µM), and (iv) both L2-b (40 µM) 
and Cu(II) (40 µM) [(v) Aβ42 (pH 9, 18 µM) with L2-b (40 µM) and Cu(II) (40 µM) is also 
presented]. Consistent with data shown here, the gray signal represents a currently 
unidentified chemical modification of the N-terminus up to, and including, residue 5 
(Figure 2.5) but not F4 (Figure 2.6). The projected location of the complex consisting of 
Aβ42, Cu(II), and L2-b in a ratio of 1:2:1 is indicated in pink. (b) IM-MS analysis of Aβ40 
(18 µM) incubated in the (i) absence and (ii) presence of L2-b (40 µM) and Cu(II) (40 
µM). Extracted arrival time distributions support the existence of three resolvable 
structural populations [Collision Cross Section (CCS) data, Table 2.2]. ........................ 48	  
Figure 2.5. Comparison of tandem MS/MS sequencing of Aβ40 (top) and the identified 
Cu(II)–L2-b-dependent chemical modification product (bottom), using the quadrupole 
isolated 3+ charge state (trap collision energy 90 V). These data support that in the 
presence of both Cu(II) and L2-b, the Aβ amino acid sequence is chemically modified at 
a position between the primary amine on the N-terminus and R5, resulting in a 
calculated mass shift of 89.24 Da. Aβ40 F4A MS data, shown below (Fig. S4), support 
the conclusion that F4 is not the target of this modification.  Spectra depicted in black 
represent a 5X base signal magnification. ...................................................................... 50	  
Figure 2.6. MS analyses of Aβ40 F4A and acetylated Aβ40 in the presence and absence 
of both L2-b and Cu(II). (a) Data for the 4+ charge states of Aβ40 F4A (18 µM) incubated 
with (ii) and without (i), L2-b (80 µM) and Cu(II) (40 µM). Data support the conclusion 
  xiii 
that F4 is not required to promote the L2-b and Cu(II) dependent chemical modification 
observed (gray signal, ii). (b) Data for the 4+ charge states of acetylated Aβ40 (18 µM) 
incubated with (ii) and without (i), L2-b (80 µM) and Cu(II) (40 µM). While Cu(II) binding 
is still observed (red signals, ii), data support the conclusion that at least one Aβ40 
primary amine is required to stabilize the interaction between Aβ40 and L2-b, as neither 
the bound nor chemically modified species is observed (pink dashed lines indicate 
location of the expected m/z values for bound states). Numerals shown above the MS 
peaks indicate the number of acetyl modifications detected for a given peak.  Mass 
analysis supports a range of 3 to 6 acetylated primary amines under our experimental 
conditions (of a possible 6).35 ......................................................................................... 51	  
Figure 2.7. Influence of L2-b on the cytotoxicity of Aβ40 and Aβ42 in the absence and 
presence of metal ions. Viability of cells (%) was determined by the MTT assay in the 
absence (gray) and presence of CuCl2 (blue) or ZnCl2 (green) and calculated relative to 
that of cells incubated only with 1% v/v DMSO. Error bars represent the standard 
deviation from three independent experiments. Conditions: [Aβ] = 10 µM; [Cu(II) or 
Zn(II)] = 10 µM; [L2-b] = 10 µM; 24 h incubation. ........................................................... 52	  
Figure 2.8. Levels of Zn(II) in the brain tissues of nontransgenic wild type (WT) and 
5XFAD transgenic mice. Amounts of Zn(II) were determined using a fluorescent dye, 6-
methoxy-(8-p-toluenesulfonamido)quinoline (TSQ), in the mossy fiber region (mf) of 
brains from (a) WT and (b and c) 5XFAD transgenic mice after intraperitoneal 
administration of (a and b) the vehicle or (c) L2-b (1 mg per kg per day) for three weeks 
beginning at three months of age (scale bar = 100 µm). The fluorescence response of 
TSQ was also shown in the zone of amyloid plaques in 5XFAD mice (shown by arrows; 
b and c). CC, corpus callosum; CA, cornu amonis; dg, dentate gyrus. (d) The 
fluorescence intensity of TSQ was quantified in the mossy fiber region (mf in a–c) of 
vehicle-treated WT (black bar; n = 6) and 5XFAD male mice (white bar; n = 10), or L2-
b-treated 5XFAD male mice (gray bar; n = 9), where the measurement was performed 
using five sagittal sections selected randomly from each animal and denoted as an 
arbitrary unit of the TSQ fluorescence [mean ± standard error of the mean (S.E.M)]. *P 
< 0.05 by one-way analysis of variance (ANOVA). ......................................................... 53	  
Figure 2.9. Effect of daily treatments with L2-b for three weeks on the amyloid deposits 
in the brains of 5XFAD male mice. Representative microscopic images of (a and b) 
4G8-immunostained or (d and e) Congo red stained brain sections of 5XFAD mice, 
which were given daily (a and d) the vehicle or (b and e) L2-b (1 mg per kg per day) via 
intraperitoneal injection for three weeks starting at three months of age (magnification = 
40×; scale bar = 100 µm). Inset in (d) and (e): enlarged micrographs of congophilic 
amyloid plaques in the cortical area (magnification, 400×; hip, hippocampus; ctx, 
cortex). To evaluate the amyloid pathology of the vehicle (black bars; n = 5)- or L2-b 
(gray bars; n = 7)-treated male 5XFAD mice, (c) the load of 4G8-immunoreactive 
amyloid deposits and (f) the number of congophilic amyloid plaques in the cortex were 
measured in five brain sections taken from each animal. *P < 0.05 by one-way ANOVA.
 ........................................................................................................................................ 54	  
Figure 2.10. Levels of Aβ in whole brain tissues of three-month-old male 5XFAD mice. 
The amounts of (a) total Aβ40, (b) total Aβ42, (c) PBS-soluble Aβ oligomers, and (d) Aβ 
  xiv 
fibrils were assessed using ELISA after three weeks of treatment with vehicle (black 
bars; n = 5) or L2-b (1 mg per kg per day; gray bars; n = 7). Bars denote the levels of 
Aβ, which were calculated from three independent experiments and expressed as 
values per gram of tissue. *P < 0.05 or **P < 0.01 by one-way ANOVA. (e) 4–20% 
(lower panels) and 16.5% (upper panels) tris-glycine gel/Western blot analyses were 
performed to visualize the Aβ monomers and aggregates, respectively, in the brain 
tissue lysates of wild type (WT; left panels) and 5XFAD male mice (right panels). ........ 55	  
Figure 2.11. Learning and memory abilities of three-month-old male wild type (WT) and 
5XFAD male mice treated with vehicle (black and white bars) and L2-b (gray), 
measured using the Morris water maze task. (a) The escape latency time was counted 
every day during the period of the 21st–25th daily treatments of either vehicle or L2-b 
and the probe trials were performed on the day of the final 25th treatment to measure (b) 
how quickly the mice reach and (c) how long they spend in the target quadrant (NW, 
highlighted in gray; circles show images of the representative tracks of the mice in the 
water maze). *P < 0.05 or **P < 0.01 by one-way ANOVA (n = 6, 13, and 14 for vehicle-
treated WT and vehicle-/L2-b-treated 5XFAD mice, respectively). ................................ 56	  
Figure 3.1. Structures of 1-4 and summary of reactivity. 1, N1-(pyridin-2-
ylmethyl)benzene-1,4-diamine; 2, 4-morpholino-N-(pyridin-2-ylmethyl)aniline; 3, 3,5-
dimethoxy-N-(pyridin-2-ylmethyl)aniline; 4, N1-((1H-pyrrol-2-yl)methyl)-N4,N4-
dimethylbenzene-1,4-diamine. ....................................................................................... 71	  
Figure 3.2. Synthesis of (a) 4-nitro-N-(pyridin-2-ylmethyl)aniline and (b) 1. .................. 72	  
Figure 3.3. Solution speciation studies of 1-3. Variable pH titrations of (a) 1 (50 µM), (c) 
2 (20 µM), or (e) 3 (100 µM) were monitored by UV-Vis. The resulting spectra were fit to 
obtain (g) pKa values and plot (b,d,f) speciation diagrams. FL = Fraction of ligand with at 
the specified protonation state. Charges omitted for clarity. Note that 4 was not 
determined for solution speciation due to limited stability in solution (100 mM NaCl, 10 
mM NaOH). .................................................................................................................... 73	  
Figure 3.4. Effect of the compounds on metal-free and metal-induced Aβ aggregation. 
(a) Scheme of inhibition experiments: freshly prepared Aβ (25 µM) in the presence or 
absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) was mixed without (lane C) or 
with compounds 1-4 (50 µM, lanes 1-4) and incubated at 37 oC with constant agitation 
for 24 h. Gel/Western blot analysis of the molecular weight distribution of the resulting 
(b) Aβ40 and (c) Aβ42 species using anti-Aβ antibody (6E10). (d) Morphologies of the 
Aβ40 aggregates as observed using TEM (scale bar = 200 nm). .................................... 74	  
Figure 3.5. Ability of 1-4 to disrupt pre-formed metal-free and metal−Aβ aggregates. (a) 
Disaggregation experiment scheme: Metal-free and metal induced aggregates of Aβ 
were generated by incubating mixtures of freshly prepared Aβ40 or Aβ42 (25 µM) in the 
presence or absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) at 37 oC with 
agitation. After 24 h, samples were treated with 1-4 (50 µM) and incubated for an 
additional 24 h. Gel electrophoresis and Western blot analysis of the molecular weight 
distribution of the resulting (b) Aβ40 and (d) Aβ42 species using anti-Aβ antibody (6E10). 
Morphologies of the (c) Aβ40 and (e) Aβ42 species as observed using TEM (scale bar = 
200 nm). ......................................................................................................................... 75	  
  xv 
Figure 3.6. Ability of 1-4 to change the morphology of Aβ40 in inhibition experiments. 
Images were obtained by TEM (scale bar = 200 nm). .................................................... 77	  
Figure 3.7. Inhibitory activity of compounds at higher metal ion concentrations on Aβ40 
aggregation (inhibition experiment). The ability of compounds to modulate the 
aggregation pathway of Aβ40 in the presence of 1 equiv (left, 50 µM), 2 equiv (middle, 
100 µM), and 5 equiv (right, 200 µM) of (a) Cu(II) or (b) Zn(II) was studied by 
gel/Western blots with an anti-Aβ antibody (6E10). ........................................................ 77	  
Figure 3.8. Biological activities of 1-4. (a) Antioxidant activity of 1-4 in the presence of 
cell lysates as evaluated by the Trolox equivalent antioxidant capacity (TEAC) assay. All 
values relative to vitamin E analog Trolox, 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid. (b) Inhibition of Cu(I/II)−triggered Fenton-like ROS production by 1-3 
(125 µM) as measured by the 2-deoxyribose assay ([Cu(II)] = 10 µM). *4 was not tested 
due to limited solubility in the assay buffer. (c) The toxicity of 1-4 as assessed in fetal 
mouse neuron cultures in the absence of metals. (d) The toxicity of 1-4 (20 µM) and the 
ability to mediate cytotoxicity of Aβ40 (20 µM) and Aβ42 (20 µM) in the absence (left, 
gray) and presence of CuCl2 (middle, blue; 20 µM) or ZnCl2 (right, green; 20 µM) was 
studied with M17 cells. C : samples without compounds. Viability of cells (%) was 
calculated relative to that of cells incubated only with 1% v/v DMSO. Error bars 
represent the standard deviation from three independent experiments. Note that 4 was 
not studied with Aβ species due to its noticeable toxicity with Cu(II) in the absence of 
the peptides. ................................................................................................................... 78	  
Figure 3.9. Stability studies of 1-4 in metal-free conditions by UV-Vis and ESI(+)MS. 
The stability of 1-4 (50 µM) by (a, e, i, m) UV-Vis in 20 µM HEPES, 150 µM NaCl, pH 
7.4 over 5 h (blue: immediately after addition of sample; orange: after 5 h incubation at 
37 oC) and by ESI(+)MS (b, f, j, n) immediately after addition of sample and (c, g, k, o) 
after incubation at 37 oC for 5 h in ddH2O. (d, h, l, p) Structures and masses of 
molecules observed in the ESI(+)MS studies. ................................................................ 80	  
Figure 3.10. Stability studies of 1-4 in the presence of Cu(II) by UV-Vis and ESI(+)MS. 
The stability of 1-4 (50 µM) in the presence of Cu(II) (25 µM) by (a, e, j, n) UV-Vis in 20 
µM HEPES, 150 µM NaCl, pH 7.4 over 5 h (blue: immediately after addition of sample; 
green: after 0.5 h incubation; orange: after 5 h incubation at 37 oC) and by ESI(+)MS (b, 
f, k, o) immediately after addition of sample and after incubation at 37 oC for (g) 0.5 h, 
and (c, h, l) 5 h in ddH2O. (d, i, m, p) Structures and masses of molecules observed in 
the ESI(+)MS studies. ..................................................................................................... 83	  
Figure 3.11. Solution speciation studies of Cu(II)−3 complexes. UV-Vis titration spectra 
for (a) Cu(II)−3 were fit to determine (c) stability constants (logβ) of Cu(II)−L species and 
(b) used to generate speciation diagrams (FCu = Fraction of free Cu and Cu(II)−L). 
Parenthesis indicate that the error is in the last digit of the values. Conditions: Cu(II):L = 
1:2, [3] = 50 µM; samples were incubated at room temperature for 24 h before titrations. 
Charges omitted for clarity. ............................................................................................. 83	  
Figure 3.12. Computational investigations of the molecular level properties of 1-4 and 
proposed mechanistic pathways. (a) Scheme of the SN2 Cu(II)-assisted hydrolysis of 1-
4 and the DFT optimized transition state structures of the hydrolysis of (b) 3 and (c) 4. 
  xvi 
The bond lengths of bonds being broken and being formed are shown. For clarity, the 
water molecules coordinating to Cu(II) are represented with sticks (red: O; blue: N; gray: 
C; white: H; orange: Cu). (d) Scheme of oxidation of p-phenylenediamines. (e) 
Isosurface plot of SOMOs of 1-4 with an isovalue of 0.02 au. Red represents the 
electron phase while green represents the opposite phase. (f) Calculated activation 
energies in the gas and in solvent (water) phase as well as ionization potentials and 
chemical hardness (η; η ≈ εLUMO−εHOMO) for 1-4. (g) Proposed pathways for the differing 
activities of 1-4 toward metal-free or metal-associated Aβ species. ............................... 85	  
Figure 4.1. Structures of stilbene derivatives designed to target metal-free and metal-
bound Aβ and modulate their reactivity. L2-b = N1,N1-Dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine; 1 = N1-(pyridin-2-ylmethyl)benzene-1,4-diamine; 2 = 4-
morpholino-N-(pyridin-2-ylmethyl)aniline; 3 = 3,5-dimethoxy-N-(pyridin-2-
ylmethyl)aniline; 4 = N1-((1H-pyrrol-2-yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine; 5 
= N1,N1-diethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-diamine; 6 = 4-nitro-N-(pyridin-2-
ylmethyl)aniline; 7 = N1,N1-dimethyl-N4-(1-(pyridin-2-yl)ethyl)benzene-1,4-diamine; 8 = 
N1,N1-dimethyl-N4-(quinolin-2-ylmethyl)benzene-1,4-diamine; 9 = N1,N1-dimethyl-N4-((1-
methyl-1H-imidazol-2-yl)methyl)benzene-1,4-diamine. ................................................ 101	  
Figure 4.2. Proposed mechanisms for reactivity of 1-9 with Aβ or metal–Aβ. (a) Ligand 
(L) forms a transient ternary complex with Cu(II)−Aβ. The Cu(II) oxidizes L to form the 
cationic radical of the ligand (L+•) and the radical is transferred to Aβ resulting in the 
observed degradation of the peptide through radical-mediated cleavage. (b) L forms a 
stable ternary complex with metal−Aβ (M = Cu or Zn) resulting in the formation of a 
stable complex that redirects the aggregation of metal−Aβ reducing toxicity and 
oxidative stress. (c) Hydrolysis of L, which can be promoted by metal ions, produces a 
small molecule, DMPD, which has been show to covalently bind to Aβ controlling its 
reactivity. ...................................................................................................................... 102	  
Figure 4.3. Modulation of Aβ40 and Aβ42 aggregation by 1-9. (a) Scheme of the 
inhibition experiment. Mixtures of freshly prepared Aβ with Cu(II) (blue), Zn(II) (green), 
or no metal ions were treated with compound (lanes 1-9) and incubated for 24 h or 4 h 
before analysis. Samples excluding compound (lane    C) were also prepared as a 
control. Conditions: [Aβ] = 25 µM; [Cu(II) or Zn(II)] = 25 µM; [compound] = 50 µM; pH 
6.6 (for Cu(II)-containing samples) or pH 7.4 (for metal-free and Zn(II)-containing 
samples); 37 oC; constant agitation. Analysis of the resulting molecular weights of (b, c) 
Aβ40 and (d, e) Aβ42 species after (b, d) 24 h or (c, e) 4 h incubation in the absence (left) 
or presence of Cu(II) (middle) or Zn(II) (right) by gel electrophoresis and subsequent 
Western blotting (gel/Western blot) with an anti-Aβ antibody (6E10). .......................... 106	  
Figure 4.4. Disaggregation of preformed Aβ40 and Aβ42 aggregates by 1-9. (a) Scheme 
of the inhibition experiment. Mixtures of freshly prepared Aβ with Cu(II) (blue), Zn(II) 
(green), or no metal ions were treated with compound (lanes 1-9) and incubated for 24 
h or 4 h before analysis. Samples excluding compound (lane C) were also prepared as 
a control. Conditions: [Aβ] = 25 µM; [Cu(II) or Zn(II)] = 25 µM; [compound] = 50 µM; pH 
6.6 (for Cu(II)-containing samples) or pH 7.4 (for metal-free and Zn(II)-containing 
samples); 37 oC; constant agitation. Analysis of the resulting molecular weights of (b, c) 
Aβ40 and (d, e) Aβ42 species after (b, d) 24 h or (c, e) 4 h incubation in the absence (left) 
  xvii 
or presence of Cu(II) (middle) or Zn(II) (right) by gel electrophoresis and subsequent 
Western blotting (gel/Western blot) with an anti-Aβ antibody (6E10). .......................... 107	  
Figure 4.5. Inhibitory activity of compounds on Aβ40 aggregation at higher ratios of 
metal to compound under the conditions of the inhibition experiments (Figure 4.3a). 1 
equiv (left; 50 µM), 2 equiv (middle; 100 µM), and 5 equiv (right; 250 µM) of (a) Cu(II) 
and (b) Zn(II). ................................................................................................................ 109	  
Figure 4.6. Morphologies of metal-free Aβ and metal−Aβ. TEM studies was employed to 
observe the morphologies of (a and b) Aβ40 and (c and d) Aβ42 from (a and c) inhibtion 
(Figure 4.3b and d) and (b and d) disaggregation experiments (Figure 4.4b and d) after 
24 h incubation with 5 or 7. ........................................................................................... 109	  
Figure 4.7. Solution speciation studies of 5-8. Variable pH titrations of (a) 5 (100 µM) (b) 
6 (25 µM), (c) 7 (100 µM), and 8 (20 µM) were monitored by UV-Vis. The resulting 
spectra were fit to obtain (i) pKa values and (e-f) used to generate speciation diagrams. 
FL = Fraction of ligand with at the specified protonation state. Charges omitted for 
clarity. Note that 9 was not studied due to its limited stability in solution (100 mM NaCl, 
10 mM NaOH). ............................................................................................................. 110	  
Figure 4.8. Stability of 5-9 and L2-b in the absence of metal ions. (a-f) The UV-Vis 
spectra of 5-9 and L2-b were monitored over the course of 5 h at pH 7.4; blue: 
immediately after addition of the compound; orange: after 5 h incubation at 37 oC. (g) 
Rate of transformation and half-lives of 5-9 and L2-b in the presence and absence of 
Cu(II). aRate of decay of the absorbance peak at 300 nm for 9. bHalf life of the 
absorbance peak in minutes. cSpectral changes were too slow to accurately measure 
the rate during the duration of the experiment. Conditions: [Compound] = 50 µM; 25 µM 
HEPES, pH 7.4,150 µM NaCl; room temperature. ....................................................... 111	  
Figure 4.9. Electrospray ionization-mass spectrometry (ESI(+)MS) studies of the 
species in solution in the absence of metal ions. (a and b) 8 and (d and e) 9 were 
analyzed (a and d) immediately after addition to ddH2O and (b and e) after 5 h 
incubation at 37 oC. Assigned species for (c) 8 and (f) 9. ............................................. 112	  
Figure 4.10. Interaction of compounds with 15N-labeled Aβ40. SOFAST-HMQC NMR 
(900 MHz) spectra before (blue) and after (red) addition of 10 equiv of (a) 1, (b) 2, (c) 3, 
(d) 4, (e) 5, (f) 6, (g) 7, (h) 8, and (i) 9. ......................................................................... 114	  
Figure 4.11. Normalized chemical shift perterbations (CSPs) of 1H and 15N amide 
atoms for Aβ40 after addition of 10 equiv of compound from the SOFAST-HMQC NMR 
(900 MHz) spectra (Figure 4.10). ................................................................................. 114	  
Figure 4.12. Stability of 5-9 and L2-b in the presence of Cu(II). (a-f) The UV-Vis spectra 
of 5-9 and L2-b in the presence Cu(II) was monitored over the course of 5 h in 20 µM 
HEPES, pH 7.4, 150 µM NaCl; blue: immediately after addition of the compound; 
orange: after 5 h incubation at 37 oC. (g) Rate of transformation and half-lives of 5-9 and 
L2-b in the presence of Cu(II). aRate of decay of the absorbance peak at 473 nm, 400 
nm, 420 nm, and 420 nm for 5, 8, 9, and L2-b, respectively. bHalf life of the absorbance 
peak in minutes. cNo spectral changes were observed during the duration of the 
experiment. dRate of growth of the peak at 400 nm for 7. Conditions: [Compound] = 50 
µM;  [Cu(II)] = 25 µM; 20 µM HEPES, pH 7.4,150 µM NaCl. ....................................... 115	  
  xviii 
Figure 4.13. Electrospray ionization-mass spectrometry (ESI-MS) studies of the species 
in solution in the presence of Cu(II) and Zn(II). Mixtures of (a, b) Cu and 7 as well as 
Zn(II) and (e, f) 1, (h, i) 4, or (k, l) L2-b were analyzed (a, e, h, k) immediately after 
addition to ddH2O and (b, f, i, l) after 5 h incubation at 37 oC and (c, g, j, m) their 
structures assigned. ..................................................................................................... 116	  
Figure 4.14. Stability of 5-9 and L2-b in the presence of Zn(II). (a-f) The UV-Vis spectra 
of 5-9 and L2-b in the presence Zn(II) was monitored over the course of 5 h in 20 µM 
HEPES, pH 7.4, 150 µM NaCl; blue: immediately after addition of the compound; 
orange: after 5 h incubation at 37 oC. (g) Rate of transformation and half-lives of 5-9 and 
L2-b in the presence of Cu(II). aRate of growth of the absorbance peak at 255 nm, 500 
nm, 500 nm, 290 nm, and 253 nm for 4, 7, 8, 9, and L2-b. bHalf-life of the absorbance 
peak in minutes. cNo measurable spectral changes were observed during the duration 
of the experiment. Conditions: [Compound] = 50 µM;  [Cu(II)] = 25 µM; 20 µM HEPES, 
pH 7.4,150 µM NaCl; room temperature. ..................................................................... 117	  
Figure 4.15. Solution speciation studies of the Zn(II)−1 complex. (a) Variable pH UV-Vis 
titration spectra for Zn(II)−1 were fit to determine stability constants (c, logβ) of Cu(II)−L 
species and used to generate speciation diagrams (b, FCu = Fraction of free Cu and 
Cu(II)−L). Parenthesis indicates that the error is in the last digit of the values. 
Conditions: Zn(II):L = 1:2; [1] = 100 µM; samples were incubated at room temperature 
for 24 h before titrations. Charges omitted for clarity. ................................................... 119	  
Figure 4.16. SOFAST-HMQC NMR (900 MHz) studies with 15N-labeled Aβ40 in the 
presence of Zn(II). (a, d, g, and j) Spectra of Aβ40 before (black) and after addition of 
Zn(II) (red). (b, e, h, and k) Spectra of Aβ40 before (black) and after addition of Zn(II) and 
compound (red). (c, f, i, and l) Intesities of Aβ with Zn(II) before (black) and after 
addition of compound (red) normalized to the initial metal-free Aβ40 signal. ................ 120	  
Figure 4.17. Molecular level interaction with Aβ40 fibrils. 1H STD NMR spectra of (a) 1, 
(c) 2, (e) 4, and (g) L2-b with Aβ40 fibrils. Comparison of the STD signal intensity (red) 
with the STD reference (black) allows for the determination of the relative proximity of 
the corresponding proton to the fibrils. Normalized intensities of the STD signal mapped 
to the structures of (b) 1, (d) 2, (f) 4, and (h) L2-b. The STD effects are highlighted in 
color (green, > 75%; yellow, 50-75%; red, < 50%); no color represents the that the STD 
signal for the proton was not observed). ...................................................................... 122	  
Figure 4.18. Molecular-level interaction with Aβ40 fibrils treated with Zn(II). 1H STD NMR 
spectra of (a) 1, (c) 2, (e) 4, and (g) L2-b with Zn(II)-treated Aβ40 fibrils. Comparison of 
the STD signal intensity (red) with the STD reference (black) allows for the 
determination of the relative proximity of the corresponding proton to the fibrils. 
Normalized intensities of the STD signal mapped to the structures of (b) 1, (d) 2, (f) 4, 
and (h) L2-b. The STD effects are highlighted in color (green, > 75%; yellow, 50-75%; 
and red, < 50%; no color represents the that the STD signal for the proton was not 
observed). ..................................................................................................................... 123	  
Figure 4.19. Ability of 5-9 to mediate oxidative stress. (a) Antioxidant activity of 5-9 in 
the presence of cell lysates as evaluated by the TEAC assay. Values are relative to a 
vitamin E analog, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). (b) 
  xix 
Ability of 5-9 (125 µM) to control Cu(I/II)-triggered ROS production by Fenton-like 
reactions, as measured by the 2-deoxyribose assay ([Cu(II)] = 10 µM). ...................... 124	  
Figure 4.20. Regulation of metal-free Aβ and metal−Aβ toxicity in living cells. (a) The 
toxicity of 6, 7, and 9 (20 µM) and the ability 7 and 9 to mediate cytotoxicity of (b) Aβ40 
(20 µM) and (c) Aβ42 (20 µM) in the absence (left) and presence of Cu(II) (middle, 20 
µM) or Zn(II) (right, 20 µM) was studied in M17 cells. C = Control samples without 
compound treatment. Viability of cells (%) was calculated relative to that of cells 
incubated only with 1% v/v DMSO. Error bars represent the standard deviation from 
three independent experiments. Note that 6 was not studied with Aβ species due to its 
relative toxicity in the absence of Aβ. ........................................................................... 125	  
Figure A.1. Design approach utilized to create L3-b. The metal binding properties of 
phen (orange) was incorporated into the structure of a known Aβ interacting stilbene 
molecule generating L3-b. ............................................................................................ 142	  
Figure A.2. Solution speciation studies of L3-b. Variable pH titrations of L3-b (15 µM) in 
solution (100 mM NaCl, 10 mM NaOH) were monitored by UV-Vis. The resulting (a) 
spectra were fit to obtain (c) the pKa values and plot (b) a speciation diagram. FL = 
Fraction of ligand with at the specified protonation state. Charges omitted for clarity. . 144	  
Figure A.3. Metal binding studies of L3-b. CuCl2 binding of L3-b in the (a) absence and 
(b) presence of 10 equiv of sodium ascorbate (Asc) in 20 mM HEPES, pH 6.6, 150 mM 
NaCl (20 µM, 1% v/v DMSO). (c) Cu(I) binding of L3-b in CH3CN (20 µM, 1% v/v 
DMSO); (d) Zn(II) binding of L3-b in 20 mM HEPES, pH 7.4, 150 mM NaCl (40 µM, 1% 
v/v DMSO), as monitored by UV-Vis spectroscopy. ..................................................... 145	  
Figure A.4. Solution speciation study of the Cu(II)−L3-b complex. (a) UV−vis spectra of 
the Cu(II)−L3-b complex ([Cu(II)]/[L] = 1:2; [Cu(II)]total = 7.5 µM; 3 h incubation with L3-
b prior to pH titration, L = L3-b; room temperature). (b) Solution speciation diagram (FCu 
= fraction of free Cu and Cu complexes). (c) Stability constant (logβ) and pCu values 
determined in these investigations. Charges are omitted for clarity. Error in the 
parentheses is shown in the last digit. .......................................................................... 145	  
Figure A.5. Effect of the L3-b on metal-free and metal-induced Aβ aggregation. (a) 
Scheme of inhibition experiments: freshly prepared Aβ40 or Aβ42 (25 µM) in the 
presence or absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) was mixed without 
(−) or with L3-b (+, 50 µM) and incubated at 37 oC with constant agitation for 4 h (left) or 
24 h (right). Gel/Western blot analysis of the molecular weight distribution of the 
resulting (b,c) Aβ40 and (d,e) Aβ42 species using anti-Aβ antibody (6E10). .................. 146	  
Figure A.6. Ability of L3-b to disrupt preformed metal-free and metal−Aβ aggregates. 
(a) Disaggregation experiment scheme: Metal-free and metal induced aggregates of Aβ 
were generated by incubating mixtures of freshly prepared Aβ40 or Aβ42 (25 µM) in the 
presence or absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) at 37 oC with 
agitation. After 24 h, samples were treated with L3-b (+; 50 µM) and incubated for an 
additional 4 h (left) or 24 h (right). Gel electrophoresis and Western blot analysis of the 
molecular weight distribution of the resulting (b,c) Aβ40 and (d,e) Aβ42 species using 
anti-Aβ antibody (6E10). ............................................................................................... 147	  
  xx 
Figure A.7. Transmission electron microscopy (TEM) images of Aβ42 24 hr inhibition 
samples. Metal-free (left), Cu(II) (middle), and Zn(II) (right) samples coincubated with 
(+) or without (–) L3-b were analyzed. (Scale bar = 500 nm). ...................................... 148	  
Figure A.8. Trolox antioxidant capacity (TEAC) of L3-b. The ability of L3-b to quench 
organic ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)] radicals was 
measured in ethanol (middle) and cell lysates (right) and compared to the activity of 
known antioxidant trolox (left). ...................................................................................... 149 
Figure A.9. Cytotoxicity of L3-b. The toxicity of L3-b (10 µM) was assessed in the (a) 
absence and presence of (b) CuCl2 (10 µM) or (c) ZnCl2 (10 µM) was studied with N2a 
cells. Viability of cells (%) was calculated relative to that of cells incubated only with 1% 
v/v DMSO. Error bars represent the standard deviation from three independent 
experiments. ................................................................................................................. 149	  
Figure B.1. Design approach of cLick2 series. Metal chelation proprieties were 
incorporated into a known Aβ interaction structure to generate small molecules with the 
potential to interact with metal−Aβ complexes. cLick2-a, 2-(4-phenyl-1H-1,2,3-triazol-1-
yl)pyridine; cLick2-b, N,N-dimethyl-4-(1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)aniline; 
cLick2-c, 2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)pyridine. .......................... 157	  
Figure B.2. Synthetic scheme for the cLick2 series. ................................................... 158	  
Figure B.3. DFT calculations of the cLick2 series structures. Geometry optimized 
structures of (a) cLick2-a, (b) cLick2-b, and (c) cLick2. (d) Dihedral angles (ϕ) 
measured between the pyridine ring and the triazole ring (ϕpyridine-triazole) as well as the ϕ 
between the triazole ring and the substituted phenyl ring (ϕtriazole-phenyl). ...................... 158	  
Figure B.4. Cu(II) binding studies. CuCl2 was added to ethanolic solutions (1% v/v 
DMSO) of (a) cLick2-a (20 µM), (b) cLick2-b (40 µM), or (c) cLick2-c (20 µM). ........ 160	  
Figure B.5. Effect of the cLick2 series on metal-free and metal-induced Aβ 
aggregation. (a) Scheme of inhibition experiments: freshly prepared Aβ40 or Aβ42 (25 
µM) in the presence or absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) was 
mixed without (lane 1) or with the compounds (lane 2, cLick2-a; lane 3, cLick2-b; lane 
4, cLick2-c; 50 µM) and incubated at 37 oC with constant agitation for 4 h (left) or 24 h 
(right). Gel/Western blot analysis of the molecular weight distribution of the resulting 
(b,c) Aβ40 and (d,e) Aβ42 species using anti-Aβ antibody (6E10). ................................ 161	  
Figure B.6. Ability of cLick2 series to disrupt pre-formed metal-free and metal−Aβ 
aggregates. (a) Disaggregation experiment scheme: Metal-free and metal induced 
aggregates of Aβ were generated by incubating mixtures of freshly prepared Aβ40 or 
Aβ42 (25 µM) in the presence or absence of Cu(II) (blue, 25 µM) or Zn(II) (green, 25 µM) 
at 37 oC with agitation. After 24 h, samples were treated with nothing (lane 1), cLick2-a 
(lane 2, 50 µM), cLick2-b (lane 3, 50 µM), and cLick2-c (lane 4, 50 µM) and incubated 
for an additional 4 h (left) or 24 h (right). Gel electrophoresis and Western blot analysis 
of the molecular weight distribution of the resulting (b,c) Aβ40 and (d,e) Aβ42 species 
using anti-Aβ antibody (6E10). ..................................................................................... 162	  
 
  
  xxi 
 
List of Appendices 
 
Appendix A: Exploration of the activity of 2-(4-dimethylaminophenylazo)pyridine toward 
mediating metal−Aβ reactivity ...................................................................................... 141	  
A.1. Introduction ........................................................................................................ 142	  
A.2. Results and Discussion ..................................................................................... 142	  
A.2.1. Blood-brain barrier permeability .................................................................. 142	  
A.2.2 Metal-binding properties .............................................................................. 143	  
A.2.3. Modulation of Aβ40 and Aβ42 aggregation in the absence and presence of 
metal ions .............................................................................................................. 146	  
A.2.4. Mediation of oxidative stress ....................................................................... 149	  
A.2.5. Cytotoxicity of L3-b ..................................................................................... 149	  
A.3. Conclusions ....................................................................................................... 150	  
A.4. Experimental section ......................................................................................... 150	  
A.4.1. Materials and methods ................................................................................ 150	  
A.4.2. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) ............................................................................................ 150	  
A.4.3. Determination of solution speciation for L3-b and the Cu(II)–L3-b complex
 .............................................................................................................................. 151	  
A.4.4. Metal binding studies .................................................................................. 151	  
A.4.5. Aβ aggregation experiments ....................................................................... 151	  
A.4.6. Gel electrophoresis and Western blotting ................................................... 152	  
A.4.7. Transmission electron microscopy (TEM) images ...................................... 152	  
A.4.8. Antioxidant assay ........................................................................................ 153	  
A.4.9. Cytotoxicity studies ..................................................................................... 153	  
A.5. References ........................................................................................................ 154	  
Appendix B: Interaction of 1,4-substituted 1,2,3-triazole click compounds with 
metal−Aβ ...................................................................................................................... 156	  
B.1. Introduction ........................................................................................................ 157	  
B.2. Results and discussion ...................................................................................... 158	  
B.2.1. Design of the cLick2 series ......................................................................... 158	  
B.2.2. Interaction with metal ions .......................................................................... 160	  
B.2.3. Modulation of Aβ40 and Aβ42 aggregation in the absence and presence of 
metal ions .............................................................................................................. 160	  
B.3. Conclusions ....................................................................................................... 160	  
B.4. Experimental section ......................................................................................... 162	  
B.4.1 Materials and methods ................................................................................. 162	  
B.4.2. General synthesis of cLick2 series ............................................................. 163	  
B.4.3. Purification of cLick2-a ............................................................................... 163	  
  xxii 
B.4.4. Purification of cLick2-b ............................................................................... 164	  
B.4.5. Purification of cLick2-c ............................................................................... 164	  
B.4.6. DFT geometry optimizations of cLick2 series structures ........................... 164	  
B.4.7. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) ............................................................................................ 165	  
B.4.8. Metal binding studies .................................................................................. 165	  
B.4.9. Aβ aggregation experiments ....................................................................... 165	  
B.4.10. Gel electrophoresis and Western blotting ................................................. 166	  
B.5. References ........................................................................................................ 167	  
 
  
  xxiii 
 
List of Abbreviations 
(CuOTf)2•C6H6 Copper(I) trifluoromethanesulfonate benzene complex 
α-Syn   α-Synuclein  
3D   Three dimensional  
Aβ   Amyloid-β 
AD   Alzheimer’s disease 
Al2O3   Aluminium oxide 
ALS   Amyotrophic lateral sclerosis 
AMPA   2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid  
ANOVA  Analysis of variance 
Asc   Sodium ascorbate 
BBB   Blood-brain barrier 
BSA   Bovine serum albumin 
CA   Cornu amonis  
CC   Corpus callosum; 
CcO   Cytochrome c oxidase 
CCS   Collision cross section 
CH3CN  Acetonitrile 
clogP    Calculated logarithm of the octanol-water partition coefficient 
CNS    Central nervous system 
CO2   Carbon dioxide 
COSMO  Conductor-like screening model  
CSF   Cerebral spinal fluid 
CSP   Chemical shift perterbations 
CTE   Chronic traumatic encephalopathy 
ctx   Cortex  
Cu[(CH3CN)4]BF4 Tetrakis(acetonitrile)copper(I) tetrafluoroborate  
  xxiv 
CuCl2   Copper(II) chloride 
Cu,Zn-SOD1  Copper and zinc superoxide dismutase  
CQ    Clioquinol; 5-chloro-7-iodoquinolin-8-ol 
DCM   Dichloromethane 
ddH2O  Double-distilled water 
DFO Deferoxamine; N-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-ami-
nopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxy-
succinamide)  
DFP  Deferiprone; 3-hydroxy-1-methylpyridin-4(1H)-one  
DFP-NP  Deferiprone functionalized with polystyrene nanoparticles  
DFT   Density functional theory 
dg   Dentate gyrus 
DMPD  N,N-Dimethyl-p-phenylenediamine 
DMSO  Dimethyl sulfoxide 
DPA    Di-(2-picolyl)amine  
DTPA   Diethylenetriaminepentaacetic acid  
ECL   Enhanced chemiluminescence 
ECP   Effective-core potential  
EDTA  2,2’,2’’,2’’’-(Ethane-1,2-diylbis(azanetriyl))tetraacetic acid  
EGCG  Epigallocatechin-3-gallate  
ELISA   Enzyme-linked immunosorbent assay 
ENDIP   N1,N2-Bis(pyridin-2-ylmethyl)ethane-1,2-diamine 
ESI-MS  Electrospray ionization mass spectrometry 
ETC   Electron transport chain  
Et3N   Triethylamine 
EtOAc   Ethyl acetate  
Et2O   Diethyl ether 
FBS   Fetal bovine serum 
FTLD   Frontotemporal lobar degeneration  
Gln   Glutamine 
GSH   Glutathione  
  xxv 
H2O2    Hydrogen peroxide 
hAPP   Human amyloid precursor protein  
HD   Huntington's disease 
Htt   huntingtin 
HBD   Hydrogen bond donor 
HBA   Hydrogen bond acceptor 
Hip   Hippocampus  
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HOMO  Highest occupied molecular orbital  
HBSS   Hank’s balanced salt solution 
HSAB   Hard-soft acid base 
HRMS  High-resolution mass spectrometry 
IDP   Intrinsically disordered protein 
IM-MS  Ion mobility-mass spectrometry 
IMPY    2-(4’-Dimethylaminophenyl)-6-iodoimidazo[1,2-a]pyridine 
IP   Ionization potential 
Kd   Disassociation constant  
LUMO   Lowest unoccupied molecular orbital 
m/z    Mass-to-charge ratio 
M17 cells  Human neuroblastoma SK-N-BE(2)-M17 cells  
mf   Mossy fiber region of the brain 
MgSO4  Magnesium sulfate 
MPAC   Metal−protein attenuating compounds  
MS   Mass spectrometry 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  
MW   Molecular weight 
N2a cells  Murine neuroblastoma Neuro-2a cells 
Na2H2PO4  Sodium dihydrogen phosphate 
NADPH  Reduced nicotinamide adenine dinucleotide phosphate  
NEAA   Non-essential amino acids  
nESI   Nanoelectrospray ionization 
  xxvi 
NFT   Neurofibrillary tangles  
NH4OH  Ammonium hydroxide 
NMDAR  N-Methyl-D-aspartate receptors  
NMR   Nuclear magnetic resonance spectroscopy 
O2   Dioxygen 
O2•–   Superoxide 
PAMPA-BBB Parallel artificial membrane permeability assay adapted for the 
blood-brain barrier 
PBS   Phosphate buffered saline 
PCM   Polarizable continuum model 
PD   Parkinson’s disease 
PDVF   Polyvinylidene fluoride 
PrP   Prion protein 
PSA   Polar surface area 
PSEN1  Presenilin  
Ptau   Hyperphosphorylated tau protein  
ROS   Reactive oxygen species 
SDS   Sodium dodecyl sulfate 
SEM   Standard errors of the mean 
SMON  Subacute myelo-optic neuropathy  
SOD   Superoxide dismutase 
SOFAST-HMQC Band-selective optimized flip-angle short transient heteronuclear 
multiple quantum coherence  
SOMO  Singly occupied molecular orbitals 
SPECT  Single-photon emission computed tomography 
STD   Saturation transfer difference  
TBS   Tris-buffered saline 
TBS-T   Tris-buffered saline containing Tween 20 
TEAC   Trolox equivalent antioxidant capacity  
TEM   Transmission electron microscopy 
TfR   Transferrin receptor 
  xxvii 
ThT Thioflavin T; 4-(3,6-dimethylbenzothiazol-3-ium-2-yl)-N,N-dimethyl-
aniline 
TLC   Thin layer chromatography  
TSQ   N-(6-Methoxy-8-quinolyl)-p-toluenesulfonamide 
Trolox   6-Hydroxy-2,5,7,8-tetramethylchroman-2- carboxylic acid  
TROSY-HSQC Transverse relaxation-optimized heteronuclear single quantum 
coherence nuclear magnetic resonance spectroscopy  
Tween 20  Polyoxyethylene (20) sorbitan monolaurate 
UV-Vis  UV-Visible spectroscopy  
WT   Wild type 
ZnCl2   Zinc(II) chloride 
ZnTs   Zinc transporter proteins 
  
  xxviii 
 
Abstract 
 
Metals play an essential part in biological processes in humans. When these 
beneficial metal ions become misregulated, the resulting metal ion dyshomeostasis can 
be catastrophic. This occurs in several neurodegenerative diseases where the aberrant 
interactions of metal ions with proteins can lead to their abnormal aggregation, 
production of oxidative stress, and neuronal death (reactivity). To better understand the 
role of metal−protein complexes in the pathogenesis of these diseases, small molecules 
have been developed as chemical tools that target these complexes and mediate their 
reactivity.  
In this thesis, first, design considerations along with the approaches of developing 
and studying the activity of such molecules were discussed in the context of the most 
prevalent neurodegenerative diseases, Alzheimer’s disease (AD). Next, one such 
compound, L2-b, was demonstrated to target metal complexes of amyloid-β (Aβ), an 
AD pathological feature, over metal-free Aβ, and reduce the reactivity of these species 
using biochemical and biophysical techniques. Upon application of L2-b to 5XFAD AD 
model mice, metal−Aβ was targeted and modulated in the brain; amyloid pathology was 
reduced; and AD-associated cognitive deficits were improved. These in vivo studies are 
the first time experimental evidence has directly linked metal−Aβ to AD pathogenesis.  
Subsequent investigations developed new small molecules that could target and 
mediate abnormal metal-free and metal-induced reactivity. Initial studies began with a 
small series of stilbene-based compounds that were found to have different activity 
toward controlling metal-free Aβ and metal−Aβ reactivity despite their structural 
similarity. In-depth (bio)chemical and DFT calculations were also performed to propose 
modes of action for these molecules. This knowledge was then used to create a library 
of chemical tools that have different abilities toward mediating abnormal metal-free and 
  xxix 
metal-induced Aβ reactivity. Additionally, two more frameworks were developed and 
their ability to control metal−Aβ reactivity was explored.  
Overall, the small molecules designed and analyzed here demonstrate that 
increased mechanistic understanding of their activity allows for the development of 
compounds with targeted abilities to control the reactivity of metal−protein complexes. 
Application of such compounds in vivo could lead to the elucidation of the pathogenesis 
of these devastating diseases, which could result in effective therapeutic discovery.  
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Chapter 1  
Ligand design to target and modulate metal-protein interactions in 
neurodegenerative diseases 
 
 
 
 
 
 
 
A portion of this chapter was presented in as a publication in  Beck, M. W.; Pithadia, A. 
S.; DeToma, A. S.; Korshavn, K. J.; Lim, M. H. In Ligand Design in Medicinal Inorganic 
Chemistry; Storr, T., Ed.; John Wiley & Sons, Ltd: Chichester, West Sussex, 2014, pp. 
257. 
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1.1. Introduction  
 
1.1.1. Metals in the brain 
Understanding the function of metals in different biological environments and 
organs especially the brain (metalloneurochemistry) has been an area of particular 
interest in the past 30 years.1,2 The complex functions of the brain require suitable 
levels of metal ions for a variety of processes including neurotransmission, dioxygen 
(O2) transport, electron transfer mechanisms, and reactive oxygen species (ROS) 
detoxification (Table 1.1).1,3-13 Owing to the broad spectrum of metal ions’ action within 
the brain, precise control of their uptake, distribution, and clearance is essential for 
proper function. The misregulation and miscompartmentalization of metals, particularly 
transition metals, have been implicated as a possible source of toxicity associated with 
multiple neurodegenerative diseases (vide infra). The recent development of both 
chemical tools to study the potential involvement of metals in neurodegenerative 
diseases and therapeutics based on this hypothesis is presented in this chapter. First, 
Table 1.1. Metal ions in the brain 
Metal Ion Function in the Brain Localizationa 
Na(I) Action potential: depolarization of transmembrane voltage along the axon12 Axon 
K(I) Action potential: repolarization of transmembrane voltage along the axon12 Axon 
Mg(II) Synaptic plasticity: voltage dependent block of N-methyl-D-aspartate receptors14 Hippocampus 
Ca(II) Neurotransmission: neurotransmitter release and excitability15 Synapse 
Mn(II/IV) Enzymatic cofactor for neuronal and glial cell function, as well as neurotransmitter synthesis16 Globus pallidus 
Fe(II/III) Enzymatic cofactor for energy metabolism, O2 transport, electron transfer and neurotransmitter synthesis11 Basal ganglia 
Cu(I/II) 
Enzymatic cofactor for energy metabolism, cellular 
respiration, ROS detoxification, and neurotransmitter 
synthesis11 
Locus coeruleus 
Zn(II) Neurotransmitter and enzymatic cofactor for protein structure and conformation11 Hippocampus 
aIndicates the area with highest concentration in the brain 
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the roles of metals in neurodegenerative diseases are briefly discussed in the context of 
their normal functions. 
Transition metal ions, such as Cu(I/II), Zn(II), and Fe(II/III), have various functions 
in the brain despite occurring in trace amounts.11,17 Copper is a redox active metal 
commonly found in the +1 and +2 oxidation states. Owing to its redox properties, copper 
is involved in the function of a number of enzymes, including those for the respiratory 
activity of cytochrome c oxidase (CcO) and ROS detoxification by copper and zinc 
superoxide dismutase (Cu,Zn-SOD1),11 as well as the oxidation of Fe(II) to Fe(III) in 
ceruloplasmin.18 Additionally, copper serves as a cofactor for enzymes and proteins that 
maintain neurotransmitter and neuropeptide homeostasis. Copper is distributed to 
various parts of the brain with average concentrations of up to 400 µM in the substantia 
nigra, 2.5 µM in the cerebral spinal fluid (CSF), and 30 µM in the synaptic cleft.1,11 
Zinc is distributed in gray matter (about 500 µM), specifically the neocortex, 
amygdala, and hippocampus (where zinc concentrations can reach up to 300 µM).11,19 It 
has been suggested that Zn(II) is released from the presynapse into the synaptic cleft 
during neurotransmission, and postsynaptic uptake occurs through calcium-permeable 
2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA)-kainate 
channels.11,20 The uptake and distribution of Zn(II) throughout neuronal cells are 
performed by zinc transporter proteins (ZnTs).11,21 The role of Zn(II) in 
neurotransmission has not been completely elucidated; however, it has been reported 
that Zn(II) could inhibit N-methyl-d-aspartate receptors (NMDARs) as well as AMPA 
gated channels.11,22-25 
Iron is the most abundant metal in the body; within the brain it is primarily 
concentrated in the basal ganglia, oligodendrocytes, microglia, and neurons.26,27 Iron, 
when bound to transferrin, can be transported across the blood brain barrier (BBB) via 
transferrin receptors (TfRs) resulting in total neuronal iron concentrations ranging 
between 0.5 – 1.0 mM.28,29 Iron is typically found in the +2 and +3 oxidation states, 
depending on the environment and role in biological systems. Higher oxidation states 
can also be observed in catalytic cycles of metalloproteins (e.g., cytochrome P450). The 
oxidation state of iron is controlled by electron transfer facilitated by ferric reductases 
and ferroxidases.12,13,35 A number of functions require iron including cell respiration 
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(CcO), ROS detoxification (catalase), and neurotransmitter biosynthesis (tyrosine 
hydroxylase).11-13 Iron ion homeostasis is regulated through the iron storage protein, 
ferritin, and the iron transport protein, transferrin.11,12,36,37 
 
1.1.2. Aberrant metal–protein interactions 
Metals are not always beneficial in biology as metal ion misregulation can cause 
dysfunction. Research into neurodegenerative diseases has investigated the roles of 
aberrant metal–protein interactions upon various diseases (Figure 1.1); and 
experimental evidence has suggested that many diseases are exacerbated by metal ion 
dyshomeostasis. Abnormal metal binding could promote the formation and stabilization 
of misfolded protein conformations, accelerate protein aggregation, and/or lead to the 
 
Figure 1.1. Selected metals and proteins involved in the pathogenesis of neurodegenerative diseases. 
Alzheimer’s disease (AD; Cu, Zn, and Fe; amyloid-β (Aβ) (PDB 2LFM)30), amyotrophic lateral sclerosis 
(ALS; Cu and Zn; superoxide dismutase (SOD) (PDB 1SPD)31), Parkinson’s disease (PD; Fe and Zn; α-
synuclein (α-syn) (PDB 2KKW)32), Huntington’s disease (HD; Cu and Fe; huntingtin (htt) (PDB 4FED)33), 
and prion disease (Mn, Cu, and Zn; prion protein (PrP) (PDB 1QLX)34). 
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overproduction of ROS.1,30-34,38-40 The non-native interaction of metal ions with proteins 
could interfere with the normal functioning of each component, along with the uptake, 
transport, and release of proteins and metal ions. For example, in Alzheimer’s disease 
(AD), the misfolded protein, amyloid-β (Aβ) (Figure 1.1), which can bind metals, has 
been suggested to aggregate in the synapse where high concentrations of metal ions 
are found during neurotransmission (up to about 200−300 µM for Zn(II); about 30 µM for 
Cu(I/II)), potentially disrupting normal metal ion homeostasis.15,18,19,30,32,38,39,41,42 
Furthermore, loosely bound redox active metal ions (e.g., Cu(I/II) and Fe(II/III)) can exert 
toxic effects via the production of ROS.30,43-45 
 
1.1.3. Oxidative stress 
Oxidative stress can be defined as an imbalance between the generation and 
clearance of ROS that may ultimately cause the direct oxidation and dysfunction of 
biomolecules (e.g., DNA, proteins, and lipids).46 The high O2 consumption in the brain 
makes it especially prone to damage by ROS, and oxidative stress can easily occur if 
the mechanisms to detoxify ROS are dysfunctional. This can lead to more rapid aging, 
excitotoxicity of neurons, and neuronal death.47,48 ROS can be produced through the 
Fenton reaction and Haber-Weiss cycle (Figure 1.2) when redox active metal ions, such 
as Fe(II/III) and Cu(I/II), are misregulated and/or miscompartmentalized.40,49-51 
Mitochondrial dysfunction could be an additional source of ROS due to its role in cellular 
respiration and O2 reduction. During these processes, premature electron transfer to O2 
in the electron transport chain (ETC) could result in the generation of superoxide (O2•−), 
a potent ROS.48  
Defense mechanisms against ROS utilize metalloenzymes, such as Cu,Zn-SOD1 
and catalase, as well as small molecule antioxidants, such as glutathione (GSH).52,53 
Cu,Zn-SOD1 is responsible for the disproportionation of O2•− to O2 and hydrogen 
peroxide (H2O2), which is broken down to either water or O2 and water by GSH and 
catalase, respectively.52-54 In the presence of an abnormal level of redox active metal 
ions, however, H2O2 can be cycled into the Fenton and Haber-Weiss reactions instead 
of being broken down by catalase and GSH. Through these cycles, H2O2 can be 
converted to less stable ROS (Figure 1.2).40,50,51 
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Prolonged and elevated oxidative stress has been implicated in the pathogenesis 
of several neurodegenerative diseases, including AD, Parkinson’s disease (PD), and 
amyotrophic lateral sclerosis (ALS) (vide infra). Metal ion dyshomeostasis and 
mitochondrial dysfunction could be the sources of oxidative stress in these 
neurodegenerative diseases. In AD, for example, the interaction of Aβ and redox active 
Cu(I/II) or Fe(II/III) may facilitate ROS production, resulting in oxidative damage.30,32,45 It 
has also been reported that heme−Aβ complexes can have peroxidase activity in 
AD.45,55 In PD, a pathological feature is the accumulation of Fe(III) in the substantia 
nigra of diseased neurons, which could increase the likelihood for an overabundance of 
ROS.56,57 H2O2 has also been shown to interact with Cu,Zn-SOD1, through the oxidation 
of residues near the copper metal binding site, which can cause copper release and 
subsequently deactivate the enzyme, a concern in ALS.58 Despite their similarities, 
however, each neurodegenerative disease has specific hallmarks (Figure 1.1). 
 
1.2. Alzheimer’s disease (AD) 
While aberrant metal-protein interactions are involved in multiple 
neurodegenerative diseases (Figure 1.1), the most prevalent of these diseases is AD.59 
Thus the remainder of this chapter will focus on AD. AD is hallmarked by the 
accumulation of senile plaques and neurofibrillary tangles (NFTs), composed primarily 
of Aβ, and hyperphosphorylated tau protein (ptau), respectively, in the brain.18,30,32,42-
45,59-67 Along with these histopathological characteristics, concentrations of Cu, Zn, and 
Fe are found to be elevated in ex vivo tissue samples collected from AD brains (ca. 400, 
1000, and 900 µM, respectively, in the plaques).10,30,31,42-45 It remains unclear, however, 
whether the total concentration of metals in the brain is altered or their local pools are 
 
Figure 1.2. Fenton reaction and Haber-Weiss cycle for the catalytic production of ROS by Fe(II/III). 
Similar redox chemistry occurs for Cu(I/II). 
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miscompartmentalized upon initiation and progression of AD.18,39,68 Still, the current 
consensus is that metal ion dyshomeostasis occurs in AD.30,44,60  
Additionally, in vitro studies confirm that these metals can generate complexes 
with Aβ and tau. The coordination chemistry of Aβ with metals has been extensively 
studied in vitro as summarized in Table 1.2.30-32,43,45,60,69-75 The interactions between 
metal ions and Aβ are shown to accelerate Aβ aggregation and be associated with ROS 
production via Fenton chemistry.49 It is suggested that these interactions also stabilize 
toxic, oligomeric Aβ species.30,31,76 Thus, modulation and/or disruption of these 
interactions could be a potential target for the future design of chemical tools, 
diagnostics, or therapeutics in order to understand or combat AD.30,60,63,72,77 
Unlike Aβ, information on metal binding to tau has been relatively limited. As 
shown in Table 1.2, some binding studies of Cu(II), Al(III), and Fe(II/III) with both full 
length and fragments of tau and ptau in vitro have been reported.32,78-80 Upon binding to 
ptau, Cu(II) has been shown to slightly promote its aggregation.32,78 Al(III) and Fe(III), 
but not Fe(II), could also be involved in enhancement of ptau aggregation.32,78-80 Despite 
these initial studies, the interactions of metals and tau/ptau and the role of 
metal−tau/ptau species in AD pathogenesis have not yet been uncovered. 
 
1.3. Ligand design to target and modulate metal−protein interactions 
The previous sections demonstrated that AD, similar to other neurodegenerative 
diseases, is associated with various factors. Developing adequate therapeutics is 
difficult due to a lack of understanding of both disease etiology and the interconnection 
of multiple elements with neuropathogenesis. Current treatments for AD have focused 
on attenuating one specific pathogenic factor and consequently only offer symptomatic 
relief instead of disease-modifying effects.81-85 Given the role of metals in AD, metal 
chelation therapy has been suggested as a method to disrupt disease-related 
metal−protein interactions as well as restore metal ion homeostasis and proper protein 
cellular functions in the body.81 In order to control the interactions between metal ions 
and misfolded proteins in AD, metal chelating agents with traditional applications in 
metal overload diseases, along with other common chelating compounds (Figure 1.3), 
were employed and shown to modulate this interaction to varying extents in vitro.81,86-98  
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Table 1.2. Amino acid residues and binding affinities for metal−protein complexes involved in ADa 
Metal ion Amyloid-β  (Aβ)40,70,73 Tau40,78 
Fe(II) CNb = 6 
 
Asp1, Glu3, His6, His13 or 
His14, Ala2 (backbone 
carbonyl), N-terminal amine 
 
(Kd = 10-4 M) 
 
Cu(I) CN = 2 
 
Two His residues 
 
(Kd = 10-14 or 10-7) 
 
Cu(II) CN = 4 
 
Component I (3N1O) 
[His6, His13, His14, and either 
Asp1-Ala2 (backbone carbonyl) 
or Asp1] or [N-terminal amine, 
two His residues, and Asp1-
Ala2 (backbone carbonyl) or 
Asp1] 
Component II (3N1O) [His6, 
His13, His14, and Ala2 
(backbone carbonyl)] or [N-
terminal amine, Ala1-Asp2 
(deprotonated backbone 
amide), Ala2-Glu3 (back 
carbonyl), one His residue] 
(4N) [His6, His13, His14, and 
either N-terminal amine or Ala1-
Asp2 (deprotonated backbone 
amide)] 
 
(Kdc = 10-11-10-7 M) 
 
 
R2 and R3 units 
His299, His329, and His330 
 
R2 and R3 units 
Cys291 and Cys322 
 
(Kd = 10-6 M) 
Zn(II) CN = 4-6 
 
His6, His13, His14, and a 
combination of Asp1 (N-
terminal amine or carboxylate), 
Arg5 (backbone amide), Tyr10, 
Glu11, a water molecule 
 
(Kd = 10-9-10-6 M) 
 
 
a Residues listed are those known to have specific interaction. 
bCN, coordination number. 
cKd, dissociation constant.  
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For example 2,2′,2′′,2′′′-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid (EDTA) was 
shown to resolubilize insoluble Cu(II)− and Zn(II)−Aβ aggregates and affect the 
morphology of Cu(II)−Aβ species generated upon co-incubation with EDTA.92,93 
Additionally, EDTA has been shown to disaggregate insoluble Al(III)-treated tau and 
ptau species.99 DFO (Figure 1.3) has also been studied as a treatment for AD. 
Administration to AD patients over two years appeared to slow the clinical progression 
of AD-associated symptoms.100 Phen (Figure 1.3), together with two of its derivatives, 
bathocuproine and bathophenanthroline, has been demonstrated to disaggregate metal-
associated Aβ aggregates into soluble species.101,102 These ligands also mitigated H2O2 
production by Cu−Aβ species, suggesting a possible use for ROS scavenging or ROS 
production control.103 Furthermore, D-penicillamine (Figure 1.3) has shown a minor 
ability to disaggregate Cu(II)-induced Aβ aggregates in vitro.104  
The application of these traditional chelators for both the study and treatment of 
AD, however, has been limited due to poor brain uptake, inadequate specificity for 
targeting aberrant metal−protein interactions, and disruption of essential metal−protein 
cellular functions due to their high metal binding affinities.81,87,88,94,105-107 Despite these 
 
Figure 1.3. Structures of selected metal chelators. EDTA, 2,2’,2’’,2’’’-(ethane-1,2-
diylbis(azanetriyl))tetraacetic acid; DFP, 3-hydroxy-1-methylpyridin-4(1H)-one; 8-HQ, 8-hydroxyquinoline; 
DFO, N’-{5-[acetyl(hydroxy)-amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino 
)pentyl]-N-hydroxysuccinamide); phen, 1,10-phenanthroline; D-penicillamine, (S)-2-amino-3-mercapto-
3-methylbutanoic acid. 
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issues, the results suggest that regulating metal−protein interactions may be a 
productive method in ligand design for chemical tools to uncover pathogenesis of AD 
and effective diagnostics or therapeutics (vide infra). 
Recent advancements in the design of tools and treatments have sought to 
specifically and simultaneously target and modulate multiple disease-related factors 
caused by deleterious metal−protein interactions by applying a “one molecule-multiple 
targets” approach. In this chapter we will focus on small molecules that specifically 
target and modulate metal−protein interactions and regulate ROS production. Such 
molecules have mainly been fashioned through three design strategies: 
functionalization, attachment/linkage, and incorporation.81,108,109 Using these 
approaches, metal binding moieties are combined with frameworks that target and 
regulate disease-related metal−protein interactions. To prevent the introduction of 
additional dyshomeostasis and misregulation of metals, the binding affinities of these 
designed molecules for metals must be balanced in the appropriate range. The affinity 
for metal ions ought to be strong enough to modulate aberrant metal−protein 
interactions but weak enough to avoid interference with essential metal−protein 
interactions for biological functions (generally, Kd ≥ 10-10 M).30,110,111 These molecules 
should also demonstrate selectivity for metal ions associated with AD (e.g., Cu(I/II), 
Fe(II), and Zn(II)) to hinder exacerbation of metal ion dyshomeostasis. Tuning these 
properties can often be achieved by consideration of basic inorganic chemistry concepts 
such as the hard-soft acid base principle, the Irving-Williams series, denticity, and the 
chelate effect.94,105,106,108 Simple theories cannot always completely describe metal 
binding properties of small molecules in the heterogeneous in vivo environment, 
however, due to multiple parameters affecting the ability of a ligand to bind to a specific 
metal ion (e.g., charge at local pH, oxidation state, stability, rate of complexation, and 
competition with biomolecules).87,108,112-114 In addition to tuning the metal binding 
properties of these molecules, the design of the moiety that targets AD-related proteins 
is important. Unfortunately, there is no set of rules governing the interaction of small 
molecules with proteins, and most of the molecules known to interact are natural 
products, discovered through experimental observations, with little structure-interaction 
relationship exploration.115 In one of the few structure-interaction relationship studies, 
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the presence of a methyl amino moiety, with the combined hydrogen bond donor 
(HBD)/hydrogen bond acceptor (HBA) properties of the amine and the hydrophobicity of 
the methyl group(s), in derivatives of thioflavin-T (ThT), a fluorescent dye that is specific 
for amyloid fibrils, has been suggested to be important for targeting Aβ fibrils.116-118 
Other structural moieties utilized to target AD-related proteins to identify and regulate 
potentially pathological metal−protein interactions are discussed later in this chapter. 
Along with targeting and modulating aberrant metal−protein complexes in AD, it is 
critical for designed compounds to be able to penetrate the BBB. Adherence to 
Lipinski’s rules for drug likeness and the use of calculated brain-blood partitioning 
values (logBB) are particularly useful in predicting passive diffusion of a ligand across 
the BBB. The restricted terms of Lipinski’s rules dictate that molecules for brain 
applications should generally have a molecular weight (MW) ≤ 450 g/mol, a calculated 
logarithm of the octanol-water partition coefficient (clogP) ≤ 5, HBD ≤ 5, HBA ≤ 10, and 
polar surface area (PSA) ≤ 90 Å2.119,120 The logBB calculation estimates the expected 
permeability based on an equation (typically defined as logBB = −0.0148 × PSA + 0.152 
× clogP + 0.139).121 Molecules with logBB values ≤ −1.00 are expected to have poor 
diffusion across the BBB.121 Alternatively, structural groups that are known to be actively 
transported through the BBB (e.g., glucose) can be added to the parent framework to 
improve uptake into the brain.95,122 Lastly, these ligands and their corresponding 
complexes should display low cytotoxicity. Overall, chemical structures capable of 
targeting and modulating abnormal metal−protein interactions, while also being 
nontoxic, bioavailable, and BBB permeable, could be employed to construct chemical 
tools to investigate the molecular basis for or as therapeutics for the treatment of 
neurodegenerative diseases. Design considerations for molecules and their effects on 
metal−protein interactions are discussed in detail in the following sections. 
 
1.3.1. Metal chelating compounds 
As discussed in the previous section, there are several issues limiting the use of 
metal chelators in vivo. This next section discusses some of the modifications made to 
frameworks of these compounds in order to improve their properties. A good example of 
several types of possible modifications comes from the work with deferiprone (DFP) 
  12 
(Figure 1.3). Glycosylated derivatives have been developed in order to both improve 
DFP’s BBB permeability and limit the interaction of this strong chelator (Kd, 
approximately 10-21 and 10-13 in a 1 : 2 M(II):DFP stoichiometry for Cu(II) and Zn(II), 
respectively; 10-12 M in a 1 : 3 M(II):DFP fashion for Fe(III)) with metals outside the 
brain.123 A DFP prochelator employed a glucose moiety that unmasks the metal binding 
site upon cleavage by β-glycosidase.95 Additionally, Orvig and co-workers have 
capitalized on the active uptake of glucose to prepare a family of DFP derivatives to 
target and modulate metal-associated Aβ.123 The core DFP framework was O-
glycosylated, and an Aβ-interacting methylamino phenyl and benzothiazolyl moieties 
were appended to the N-position. Cu(II)- and Zn(II)-induced Aβ aggregation was 
attenuated using these new compounds. When benzothiazolyl derivatives were 
appended onto the framework at the N-position, selective resolubilization of Cu(II)-
induced Aβ aggregates was visualized, suggesting specificity for Cu(II)−Aβ over 
Zn(II)−Aβ species.123 Deferiprone, combined with polystyrene nanoparticles (DFP-NPs), 
retains the metal binding properties of the ligand while improving its viability in cells and 
efficacy to reach the brain.124 The DFP-NP conjugates inhibited Aβ fibril formation; 
however, their influence on metal−Aβ interactions in AD has yet to be studied. 
The most well-studied metal chelator based framework for controlling 
metal−protein interactions in AD is 8-hydroxyquinoline (8-HQ; Figure 1.3), which can act 
as a bidentate chelator.125,126 Derivatives of 8-HQ have been found to modulate 
aberrant metal−protein interactions in multiple neurodegenerative diseases, including 
AD, with sufficient success to have reached clinical trials.125-127 The 8-HQ derivative 
clioquinol (CQ; Figure 1.4) is an approved topical antiseptic and was once administered 
as an oral intestinal amebicide before being pulled from the market in 1970s due to a 
possible side effect, subacute myelo-optic neuropathy (SMON).127-129 The ability of CQ 
to chelate transition metals [Kd, approximately 10-10 M for Cu(II) about 10-9 M for Zn(II)] 
and to passively cross the BBB suggests that this compound could be a viable 
treatment for neurological conditions, serving as a modulator for disease-associated 
metal−protein interactions.30,127,129-133 The proposed mechanism of action for CQ is 
twofold: (i) it can chelate metal ions from disease-related proteins, which influences 
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aggregation128,134,135 and (ii) it can act as an ionophore, possibly mitigating changes in 
metal ion homeostasis by redistributing metal ions across membranes into cells and 
areas with lower metal ion concentrations.89,134,136 Molecules possessing both of these 
properties are termed metal−protein attenuating compounds (MPACs).134  
In AD transgenic mice, the amount of amyloid plaques was lessened upon CQ 
administration with improved symptoms and no observable adverse side 
effects.127,132,137 Several human trials followed, the first of which was an uncontrolled 
study with 20 patients treated daily with an 80 mg dose of CQ for 21 days; resulting in 
patients displaying signs of improved cognitive function.137,138 Subsequent phase II 
clinical trials had similar outcomes for AD patients with moderate dementia, but patients 
with more severe AD symptoms showed less significant improvement.110,137,138  
While CQ has some properties that made it suitable to modulate aberrant 
metal−protein interactions in the brain (e.g., BBB permeability, metal binding affinity in 
optimal range), it still lacks specificity to localize within the brain and selectively target 
AD-related metal−protein interactions.139-141 In addition, scale-up reactions for clinical 
trials produced toxic di-iodinated byproducts of CQ, which prevented larger scale testing 
of CQ in humans.141 As a result, clinical trials with CQ ceased and attention has shifted 
to another 8-HQ derivative, PBT-2 (Figure 1.4), which was carefully designed to avoid 
scale-up production problems and to maximize oral bioavailability.140,142  
Initial in vitro studies of PBT-2 demonstrated that this compound has similar metal 
binding affinities for Cu(II) and Zn(II) (Kd, approximately 10-10 M for Cu(II) and Zn(II)) as 
CQ but is a superior ionophore.143 Studies with metal−Aβ have shown PBT-2 is able to 
regulate Cu−Aβ-induced H2O2 production to a greater extent than CQ.143 PBT-2 was, 
however, unable to match CQ’s ability to disaggregate metal−Aβ aggregates. In vivo, 
PBT-2 was shown to improve the cognitive abilities in AD mouse models.144 
Furthermore, PBT-2, but not CQ, could decrease abnormal tau phosphorylation in AD 
 
Figure 1.4. 8-Hydroxyquinoline (8-HQ) derivatives previously utilized in clinical trials for treating AD. CQ, 
5-chloro-7-iodoquinolin-8-ol; PBT-2, 5,7-dicholoro-2-[(dimethylamino)methyl]quinolin-8-ol. 
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mice.143 Clinical trials of PBT-2 on AD patients, like those of CQ, indicated that cognitive 
improvement between placebo and PBT-2-treated patients were only significant at 
earlier stages of the disease.138,145,146 Although PBT-2 was well tolerated in early clinical 
trials, more rigorous clinical trials will be beneficial to fully assess this compound’s utility 
improving cognition in AD.138,146 
 
1.3.2. Small molecules designed for metal−protein complexes 
As an alternative to utilizing traditional chelators and their analogs, new small 
molecules containing structural moieties to target and modulate specific AD-related 
metal−protein interactions have been developed (vide infra). Some of these molecules 
were constructed by connecting structural moieties for metal chelation and protein 
interaction (i.e., linkage approach), or installing a metal chelation site into a protein-
targeting structure (i.e., incorporation approach).81,109,147 
ThT (Figure 1.5) has a high affinity for Aβ fibrils (nanomolar Kd).116-118 Thus, 
several compounds have been based on its framework to target metal−Aβ species and 
modulate the interaction between metal and Aβ. The first reported example is XH1 
(Figure 1.5) which is composed of two ThT-like molecules linked with 
diethylenetriaminepentaacetic acid (DTPA), a strong metal chelator for Fe(II), Fe(III), 
Cu(II), and Zn(II) (Kd, about 10-16, 10-28, 10-21, and 10-18 M, respectively).148 XH1 
influenced Zn(II)-induced Aβ aggregation in vitro and reduced plaque load in an AD 
mouse model.148 Moreover, when compared with DTPA’s effects on Zn(II)-triggered Aβ 
aggregation in vitro, XH1 was able to decrease aggregation by about 50% more, which 
demonstrates the value of having moieties targeting both metal ions and proteins 
simultaneously to disrupt aberrant metal−protein interactions. 
FC1 (Figure 1.5) is another multifunctional molecule derived from the ThT 
framework. The molecule is based on a neutral ThT backbone in which the 
dimethylamino group is replaced with the moderate metal binding moiety di-(2-
picolyl)amine (DPA) (Kd, about 10-9 M for Cu(II) and 10-7 M for Zn(II)).149 FC1 was found 
to partially transform Cu(II)− and Zn(II)−Aβ aggregates into small, amorphous 
aggregates. When HeLa cells exposed to metal−Aβ were treated with FC1, however,
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increased toxicity was observed, implying that FC1 may stabilize the generation of toxic 
Aβ oligomers.149 
Mirica and co-workers took a similar approach to the design of L1 and L2 (Figure 
1.5) where a dipyridylmethyl (L1) or a pyridylmethyl (L2) group was installed onto a ThT 
derivative with the dimethylaminophenyl group replaced with one derived from o-vanillin, 
previously shown to interact with Aβ.150 As expected, tetradentate L1 could bind Cu(II) 
and Zn(II) more strongly than tridentate L2 (Kd, about 10-10 M versus 10-8 M for Cu(II); 
about 10-8 M versus 10-7 M for Zn(II)). Moreover, for Aβ interaction, L2 (Ki about 30 nM) 
was able to bind more strongly to Aβ fibrils than L1 (Ki about 200 nM). Despite these 
differences both L1 and L2 were capable of inhibiting the formation of metal−Aβ 
aggregates as well as disaggregate preformed aggregates. Similar to FC1, however, 
 
Figure 1.5. Structures of thioflavin-T (ThT) derivatives. ThT, 4-(3,6-dimethylbenzothiazol-3-ium-2-yl)-N,N-
dimethylaniline; XH1, ([(4-(benzothiazol-2-yl)phenylcarbamoyl)methyl]-{2-[(2-{[(4-(benzothiazol-2-
yl)phenylcarbamoyl)methyl](carboxymethyl)amino}ethyl)(carboxymethyl)amino] ethyl}amino)acetic acid; 
FC1, N,N-bis(pyridin-2-ylmethyl)-3a,7a-dihydrobenzothiazol-2-amine; L1, 4-(3a,7a-dihydrobenzothiazol-2-
yl)-2-methoxy-6-((methyl(pyridin-2-ylmethyl)amino)methyl)phenol; L2, 2-((bis(pyridin-2-
ylmethyl)amino)methyl)-4-(3a,7a-dihydrobenzothiazol-2-yl)-6-methoxyphenol; HBTI, 2-(benzothiazol-2-
yl)-4-iodophenol; HBXI, 2-(benzoxazol-2-yl)-4-iodophenol; and BMI, 2-(1H-benzimidazol-2-yl)-4-
iodoaniline. 
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treatment of N2a cells with Aβ, Cu(II) or Zn(II), and L1 or L2 resulted in increased 
toxicity over L1- or L2-untreated cells.150 
HBX, HBT, and BM (iodinated forms; Figure 1.5) were discovered by in silico 
screening commercially available ThT derivatives for BBB permeability, antioxidant 
properties, and synthetic ease of iodination for possible use as imaging agents.151 The 
properties of Aβ interaction (ThT) and metal chelation (a portion of ThT and a phenol or 
aniline ring) were introduced into one framework. The iodinated forms of these 
compounds, HBXI, HBTI, and BMI (Figure 1.5), were found to be mostly neutral at 
physiological pH, suggesting that they may passively cross the BBB. Furthermore, all of 
the derivatives were able to coordinate Cu(II) and Zn(II) with Kd values similar to CQ as 
well as inhibit metal-induced Aβ aggregation.151 
Stilbene derivatives, previously used as imaging agents for Aβ aggregates, have 
demonstrated an ability to target Aβ fibrils with nanomolar binding affinities (Figure 
1.6a).152-154 L1-b (Figure 1.6a) was designed by incorporating two nitrogen donor atoms 
into the structure of the stilbene derivative (for Aβ interaction) to impart metal 
chelation.102 This compound was able to modulate metal-induced Aβ aggregation and 
diminish metal−Aβ-induced cytotoxicity.155 Owing to limited solubility of L1-b in aqueous 
media, the reduced amine form, L2-b (Figure 1.6a), was designed to combat this 
problem.156 L2-b was capable of binding metal ions with affinities for Cu(II) and Zn(II) 
(Kd, about 10-10 and 10-6 M, respectively) in the appropriate range needed to target 
metal-associated Aβ. Two dimensional 1H-15N Transverse relaxation-optimized-
heteronuclear single quantum coherence nuclear magnetic resonance spectroscopy 
(TROSY-HSQC) NMR demonstrated L2-b could interact directly with Aβ near the metal 
binding region. As a result, L2-b could control metal-mediated Aβ aggregation pathways 
in vitro and reduce the toxicity induced by metal−Aβ species in human neuroblastoma 
M17 cells. Additionally, it was shown to disaggregate ex vivo Aβ plaques in brain 
homogenates obtained from human AD patients.156 
Another compound, IMPY (2-(4′-dimethylaminophenyl)-6-iodoimidazo[1,2-
a]pyridine) (Figure 1.6b), was developed as an imaging agent for Aβ plaques.153 IMPY 
binds to Aβ fibrils, and this property was exploited by using this framework as a
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template to design new molecules for targeting and controlling metal−Aβ interactions. A 
hydroxy group was incorporated into the IMPY framework to produce K0 (Figure 1.6b) 
which could bind Cu(II) and modulate Cu(II)-triggered Aβ aggregation in vitro.102 For the 
second generation of compounds, the metal chelation site was modified from an N,O 
donor atom site to an N,N donor atom site by incorporating a single N donor atom into 
the IMPY structure, generating K2.157 These compounds were able to moderately 
regulate Cu(II)- and Zn(II)-mediated Aβ aggregate formation and disassembly.157 
 
Figure 1.6. Structures of small molecules designed based on the frameworks of (a) the stilbene 
derivative, (4-(dimethylamino)-4’-iodostilbene); (b) IMPY, ((2-(4’-dimethylaminophenyl)-6-iodoimidazo[1,2-
a]pyridine)); and (c) diphenylpropynone, (3-(4-(dimethylamino)phenyl)-1-(4-iodophenyl)-2-propyn-1-one. 
L1-b, N1,N1-dimethyl-N4-(pyridin-2-ylmethylene)benzene-1,4-diamine; L2-b, N1,N1-dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine; K0, 2-[4-(dimethylamino)phenyl]imidazo[1,2-a]pyridin-8-ol; K2, 6-(6-
iodoimidazo[1,2-a]pyridin-2-yl)-N,N-dimethylpyridin-3-amine; DPP2, 3-(4-(dimethylamino)phenyl)-1-
(pyridin-2-yl)prop-2-yn-1-one; C2, (E)-3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-en-1-one; P2, 3-
(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)propan-1-one; PA2, N-(4-(dimethylamino)phenyl) picolinamide. 
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The compound DPP2 (Figure 1.6c) was generated by the installation of an N 
donor atom into a proposed Aβ imaging agent based on a diphenylpropynone 
framework.158 The N,O donor atom metal binding site of DPP2 could bind Cu(II) with 
high nanomolar Kd, control both metal-free and metal-induced Aβ aggregation, and 
disaggregate preformed aggregates. Moreover, DPP2 has the potential to cross the 
BBB passively, as confirmed by an in vitro assay.158 The application of DPP2, however, 
was limited by its low micromolar cytotoxicity, possibly due to the carbonyl-triple bond 
moiety acting as a Michael acceptor which could react with biomolecules forming 
covalent adducts.158,159 Thus, DPP2 was recently structurally modified to ameliorate its 
cytotoxicity while maintaining BBB permeability.159 The triple bond of DPP2 was 
reduced to a double or single bond, to generate new compounds, C2 and P2 (Figure 
1.6c), respectively. In addition, PA2 (Figure 1.6c) was designed by replacing the 2-
methylpyridine in L2-b (Figure 1.6a) with the 2-pyridyl ketone from DPP2 (Figure 1.6c). 
All of these derivatives maintained DPP2’s BBB permeability; noticeably, their reactivity 
with metal-free Aβ and metal−Aβ species was altered.159 The diminished reactivity of P2 
and C2, compared with DPP2, is believed to stem from increased flexibility of the overall 
structure. In contrast to DPP2 and C2 which could modulate metal-free as well as 
metal−Aβ aggregation, PA2 was only able to modulate the aggregation of metal−Aβ 
species. Structural modification of DPP2 was shown to reduce cytotoxicity.159 C2 with a 
double bond was slightly less cytotoxic than DPP2; complete removal of an unsaturated 
bond in P2 and PA2 demonstrated the greatest reduction in cytotoxicity.159 In all of the 
above Aβ imaging agent-based molecules, maintaining the dimethylamino group in the 
frameworks proved important for activity. This highlights the value of selecting and 
retaining key structural groups and backbones from molecules known to interact with Aβ 
for the design of new compounds to target and modulate metal−Aβ 
species.102,156,157,159,160 
 
1.3.3. Other relevant compounds 
Pyridine-based compounds have been developed to interrogate metal−Aβ 
interactions in AD (vide infra). Specifically, ENDIP (N1,N2-bis(pyridin-2-ylmethyl)ethane-
1,2-diamine) (Figure 1.7), a tetradentate ligand, has demonstrated its ability to modulate 
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Cu(II)- and Zn(II)-induced Aβ aggregation by chelating the metal from Aβ.161 The 
binding affinities of this ligand (Kd, about 10-12 M for Cu(II); about 10-7 M for Zn(II)) are 
also appropriate for interaction with metal−Aβ species rather than other metalloproteins 
present in the brain.71,161 Compound L1’ (Figure 1.7) also contains a pyridyl group, 
along with a triazole moiety, to manipulate metal−Aβ interactions.162 L1’ was shown to 
influence Cu(II)- and Zn(II)-mediated Aβ aggregation in vitro.162 These data suggest that 
pyridine moieties could be utilized for the development of small molecules for the 
regulation of metal−protein interactions, if optimized for specific protein targets (vide 
infra). 
Derivatives of cyclam and cyclen (Kd, approximately 10-28 and 10-23 M for Cu(II), 
respectively)163,164 are also of interest in the design of agents to target metal−Aβ species 
and modulate their interaction and reactivity in AD. Initial studies suggested that Co(III)-
cyclen (Co(III)-cyc) complexes were able to proteolytically cleave Aβ by hydrolysis of 
amide bonds.165 This finding has led to the construction of cyc-KLVFF and cyc-
curcumin (Figure 1.7), two synthetic analogs of Aβ targeting molecules produced 
through the linkage approach.163 KLVFF is the self-recognition motif in Aβ.163 This 
compound could coordinate Cu(II) and disrupt Cu−Aβ aggregates in vitro as well as 
cleave Aβ oligomers.163 Cyc-curcumin has shown a similar ability to modulate Cu-
induced aggregation and proteolytically cleave Aβ; however, it has been neither as 
potent nor as stable under aqueous conditions as cyc-KLVFF. One drawback to the 
use of cyclen and cyclam are their high binding affinities for Cu(II) and Zn(II), which may 
 
Figure 1.7. Structures of pyridine- and cyclen-based ligands. ENDIP, N1,N2-bis(pyridin-2-ylmethyl)ethane-
1,2-diamine; L1’, 4-(2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)morpholine; and cyc-curcumin, 4-
((1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl)-2-methoxyphenyl (2-(1,4,7,10-
tetraazacyclododecan-1-yl)acetyl)glycinate. 
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allow them to perturb metalloproteins nonspecifically and further disrupt metal ion 
homeostasis (vide supra). These results, however, lend support to the potential of 
covalently linked small molecules and peptides to target and mediate metal−protein 
interactions in neurodegenerative diseases.163 
 
1.3.4. Naturally occurring molecules 
Naturally occurring compounds (in particular, polyphenolic compounds) have also 
been investigated for their ability to probe and influence metal−protein interactions in 
neurodegenerative diseases.43,81 A polyphenolic flavonoid, myricetin (Figure 1.8), was 
studied by Lim and co-workers.166 Myricetin was observed to influence metal-induced 
Aβ aggregation to a greater extent than metal-free Aβ aggregation in vitro, as well as 
diminish toxicity related to metal−Aβ species, proposing a possible use in AD research 
and treatment.166 The polyphenolic compound from green tea, epigallocatechin-3-
gallate (EGCG; Figure 1.8), has been studied to understand and treat numerous 
diseases, including AD (vide infra). EGCG could lower Aβ-related neurotoxicity and 
generate non-toxic Aβ oligomers under both metal-free and metal-present conditions.167-
169 The molecular mechanisms of these effects toward Aβ and metal−Aβ were recently 
investigated using biochemical and biophysical methods.170 EGCG could form 
 
Figure 1.8. Structures of selected, naturally occurring compounds. Myricetin, 3,5,7-trihydroxy-2-(3,4,5-
trihydroxyphenyl)-4-chromenone; EGCG, [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 
3,4,5-trihydroxybenzoate; resveratrol, 3,4’,5-trihydroxy-trans-stilbene; curcumin, (1E,6E)-1,7-bis-(4-
hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione. 
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complexes with metal-free Aβ as well as metal-associated Aβ, showing compaction of 
Aβ conformations.170,171 
Another polyphenol, resveratrol (Figure 1.8), a plant-derived antioxidant, is of 
particular interest in the study of metal−Aβ species. Conflicting reports on the effects of 
resveratrol on Aβ aggregation have been made, and these discrepancies arise from the 
different methodologies employed in sample preparation.172-174 Based on these studies, 
no significant alteration in Cu(II)-associated Aβ aggregation by resveratrol has been 
shown.172 Studies have indicated, however, that resveratrol could be a potent 
antioxidant against ROS generated by Cu(I/II)−Aβ and Fe(II/III)−Aβ, suggesting that 
further investigations on this framework are warranted.172 
Additionally, curcumin (Figure 1.8), a naturally occurring curcuminoid found in 
turmeric, has been studied for its ability to interact with metal−protein complexes found 
in neurodegenerative diseases.175-177 Curcumin has antioxidative, anti-inflammatory, 
and anti-microbial properties similar to other natural products used as possible 
therapeutic agents for multiple neurodegenerative diseases.176 Curcumin is also shown 
to interact with metal−Aβ species.176,177 It has an approximately micromolar and 
nanomolar Kd values for Cu(II) and Aβ, respectively.177,178 These properties allow it to 
alter the aggregation pathway of Aβ in the presence of metal ions and, at low 
concentrations, scavenge ROS generated by metal ions.179 Owing to its poor solubility 
and bioavailability as well as its instability in aqueous media, structural modifications are 
needed to improve the viability of this framework prior to further use as a chemical tool 
or in therapeutic applications.175 
 
1.4. Methods to study the ability of small molecules to mediate the aberrant 
interaction of metal ions and proteins 
There are many different methods to analyze and characterize the ability of small 
molecules discussed above to mediate the interaction of metal ions and proteins 
involved in AD. In the following sections, the techniques employed in this thesis to 
determine and describe the activity of these molecules to modulate the metal-free and 
metal-induced aggregation of proteins, mediation of oxidative stress, and alleviation of 
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toxicity are outlined. Additionally, techniques to understand the molecular level 
interactions between the compounds described herein and metal-free and metalated 
proteins are discussed along with methods used to characterize physical properties, 
such as BBB permeability and metal binding.  
 
1.4.1. Techniques for determining blood brain barrier permeability  
As BBB permeability is an important feature it should be one of the first design 
features considered. In addition to using calculated logBB values and Lipiniski’s rules to 
determine possible blood brain barrier permeability, as previously discussed, other in 
vitro and in vivo methods were employed herein. The parallel artificial membrane 
permeability assay adapted for the blood brain barrier (PAMPA-BBB) is a common 
assay for determining ability to passively diffuse across the blood brain barrier.180-182 
This assay simulates the blood brain barrier using a porcine brain lipid-soaked 
membrane (Figure 1.9). The diffusion of a compound across this membrane from a 
buffer that contains the molecule (donor well) to a new buffer (acceptor well) is 
measured and logPe values are calculated using the following ‘two-way flux’ equation: 
CA(t) = M/(VD + VA) + (CA(0) – M/(VD + VA))e–PeA(1/VD + 1/ VA)t where CA(t) is the 
concentration of the compound in the acceptor well at time t, M is the total amount of 
compound in the system, VD is the volume of donor well, VA is the volume of the 
acceptor well, CA(0) is the concentration of the compound in the acceptor well at the 
beginning of the experiment, Pe is the effective artificial-membrane permeability, and A 
is the area of the membrane.180-182 
 
Figure 1.9. Illustration of the ‘sandwiched’ wells of the PAMPA-BBB assay. Compound in the donor well 
diffuses across a lipid membrane in the acceptor well. After a set amount of time the concentration of the 
compound in both wells is determined and used to calculate its permeability value (logPe).  
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Another factor for BBB permeability that needs to be considered is the charge of 
the compound, since neutral molecules typically passively diffuse across the BBB more 
readily.119,183 pKa values and thus the charge at physiological pH (7.4) can be obtained 
through multiple methods,184 however, variable pH titrations, monitored by UV-Vis, were 
employed here. This method was chosen as it is very sensitive and does not require for 
high concentrations of compound (> 10-6 M).184 To obtain pKa values, the assumption 
that each species has different UV-Vis spectra is made and special software is typically 
employed to fit the spectral data.184,185 
While calculations and in vitro methods are useful to screen for passive diffusion 
across the BBB, measuring uptake of a compound in vivo is required to confirm BBB 
permeability due to the complexity of the BBB and the in vivo environment.186 In 
principle, these studies are straight forward: the amount of compound in the brain is 
determined after a one time dose.186 The animal model utilized, however, must be 
carefully considered as different phenotypes may result in varied BBB 
permeabilities.187,188 Thus, CD1 mice are typically employed for these studies as their 
heterozygosity is similar to wild mice and humans.188  
 
1.4.2. Strategies for studying the interaction of compounds with metal ions, 
proteins, and metal−protein complexes 
 The ability of the molecules to interact with metal ions can be explored by 
observing changes in the UV-Vis spectra of the molecules upon addition of metal ions. 
More detailed studies, however, are required to determine the Kd values and the 
stoichiometry of the metal complexes at physiological pH. UV-Vis variable pH titration 
studies can be carried out on compounds that are stable in the presence of metal ions 
and their Kd estimated by utilizing the concentrations of unchelated metal in the solution 
at a given pH (pM = −log[Munchelated]).102,158,189,190  
 To observe the molecular level interactions between molecules, proteins, and 
metal−protein complexes, mass spectrometry (MS) and nuclear magnetic resonance 
spectroscopy (NMR) can be employed (vide infra). MS can be used to observe 
monomeric up to soluble oligomeric forms of aggregated proteins and their complexes 
with compounds.191-195 This typically requires using nano electrospray ionization (nESI) 
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which allows for the use of small sample volumes (1-3 µL of nanomolar to micromolar 
solutions) and is less sensitive to salts present in buffer.196,197 Most importantly, nESI is 
also a very soft method of ionization allowing for the observation of relatively weak, 
biologically relevant non-covalent interactions.196,197 
In addition to being able to identify the species and stoichiometry of the molecule 
binding, ion mobility MS (IM-MS) methods can be utilized to provide structural 
information on the resulting protein–ligand and metal–protein–ligand 
complexes.191,195,198,199 IM-MS measures the transit time of ions in a chamber 
pressurized an inert gas under the influence of a weak electric field which is dependent 
on their ion-neutral collisional cross section (CCS).191,195,198,199 Thus IM-MS can be used 
to study if the compound of interest causes structural changes to the protein.170,195 
 NMR can also be employed to study the molecular level interactions between 
molecules and multiple metal-free protein and metal−protein forms depending on the 
methods used. 2D 1H−15N band-selective optimized flip-angle short transient 
heteronuclear multiple quantum coherence (SOFAST-HMQC) NMR can be used to 
observe changes in the spectra of a 15N-backbone-labeled protein upon titration of a 
compound.200,201 These changes result from the interactions of the molecule with 
 
Figure 1.10. Schematic representation of the basic principles of STD NMR. The protein is selectively 
magnetically saturated (represented by orange color) and the saturation is then transferred to the bound 
ligand. The disassociation of the saturated ligand before relaxation gives rise to the STD signal, which is 
proportional in intensity to the previous proximity of ligand atoms to the protein.  
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specific residues and if the 1H−15N cross-peaks are assigned for the protein, their 
binding site can be determined.202,203 Additionally, the reappearance, partial 
reappearance, or change in signal corresponding to residues involved in metal binding 
can also give information on the compound’s interaction with the metal ion component 
of the metal−protein complex.156,204  
 Another NMR method, saturation transfer difference (STD), can also be employed 
to study the interaction of small molecules with proteins in the absence and presence of 
metal ions.201,205 STD NMR produces an atomic-level map of the compound’s atoms 
that are in contact with the protein species of interest allowing for the determination of 
moieties that are important for interaction.205-207 This is achieved by exploiting the 
dynamics of ligand binding (Figure 1.10).205-207 Since the noncovalent binding of a 
compound with a protein and metal−protein species is labile, the protein is magnetically 
saturated and when the ligand binds the saturation is transferred to the compound. If 
the saturated molecule disassociates before relaxing, signal is produced proportional to 
the previous proximity of the ligand atoms to the protein or metal−protein complex.205-207 
Furthermore, unlike SOFAST-HMQC NMR, which requires the target of interest to be 
soluble during the experiment, this method can be used to study the interaction of 
compounds with aggregated forms.201  
 
1.4.3. Systems for exploring the metal-induced protein aggregation 
The classical methods of measuring the aggregation of amyloidogenic proteins are 
to use ThT (Figure 1.4) or turbidity assays to measure the progression of 
aggregation.116,117,128,208 These assays, however, can be significantly interfered with in 
the presence of small molecules and their metal complexes when their absorbance 
overlap with the assay (λex = ca. 440 nm, λem = 490 nm for ThT; ca. 350−450 nm for 
turbidity).128 Additionally, many metal ions are known to quench the fluorescence of a 
fluorophore like ThT, further limiting the application of this assay when studying metal-
induced protein aggregation.209-211 Thus, other methods outlined below were employed 
for this work.  
 Gel electrophoresis can separate protein aggregates based on size, charge, and 
molecular weight.212,213 When paired with Western blotting (gel electrophoresis/Western 
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blotting) this method can provide information on the distribution of species present in 
solution. Gel electrophoresis/Western blotting is limited, however. This method cannot 
provide any information of the type of species present (e.g., amorphous, oligomeric, and 
fibrillar) and it is only able detect forms that can penetrate into the gels.213  
Thus, other methods are required to better study the ability of small molecules to 
modulate the aggregation of metal–protein complexes. Dot blots with conformation 
specific antibodies such as A11214 and OC215 can provide identification of specific forms 
of aggregates.213,216 A11 can identify oligomeric forms which are believed to be 
particularly toxic while OC can identify aggregates having a fibrillar structure.213-215  
 
Figure 1.11. Schemes of the mechanisms of antioxidant assays. (a) The ABTS assay depends on the 
quenching of the ABTS cationic radical (ABTS+•) by a single electron transfer from the compound (Cmpd) 
being studied. ABTS = 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid. (b) In the deoxyribose assay, 
I. reduced redox active metal ions (Mn-1) oxidize in the presence of hydrogen peroxide (H2O2) to produce 
hydroxyl molecules and hydroxyl radicals. II. Hydroxyl radicals then react with and degrade 2-deoxyribose 
to form malonaldehyde in six steps. III. After a set time interval, excess thiobarbituric acid is added and 
reacted with the malonaldehyde formed in the previous step producing a chromogen with a strong 
absorbance at ca. 530 nm and water.  
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An additional method of studying the aggregates present in solution is to identify 
the morphology visually using microscopy techniques, such as transmission electron 
microscopy (TEM).208,217 Using this technique, structures can be classified as fibrils, 
protofibrils, or amorphous aggregates.217,218 Comparing morphologies produced after 
treatment with the compound can provide a more complete understanding of the effect 
of small molecules on the larger aggregates of metal−protein species. 
 
1.4.4. Approaches for studying the ability of compounds to mediate oxidative 
stress 
 There are many assays for determining the ability to mediate oxidative stress.219-
222 Careful selection of the correct assay is required in order to obtain meaningful results 
from these experiments. A particularly important point to consider is the compound’s 
mechanism of modulating oxidative stress as most of the assays are mechanism 
specific. In the following chapters, the Trolox Equivalent Antioxidant Capacity (TEAC) 
and deoxyribose assays are employed to characterize the ability of the molecules 
studied to reduce oxidative stress.  
The TEAC assay measures the ability of a compound to neutralize the organic 
radical of ABTS compared to Trolox, a water soluble vitamin E analog. This method was 
chosen as it can be used for molecules that undergo electron transfer mechanisms to 
scavenge radicals and can be monitored at a wavelength which does not interfere with 
the compounds studied (λassay = ca. 730 nm; Figure 1.11a).219,223,224 Additionally, this 
experiment is robust and can be ran in a variety of solvents including solutions which 
can simulate the complexity of biological environments such as cell lysates.201,221 
 The ability to reduce oxidative stress from Fenton-like chemistry (Figure 1.2) can 
be studied using the deoxyribose assay.201,221 In this assay, the ability of a compound to 
prevent the production of or scavenge hydroxy radicals (•OH) generated by a redox 
active metal (typically, Cu(I/II) or Fe(II/III)) through Fenton-like chemistry in the presence 
of hydrogen peroxide can be determined.225-227 This is measured by reacting 
thiobarbituric acid with the malonaldehyde (MDA) produced from the oxidation of 2-
deoxyribose by •OH producing a chromogen (λmax = ca. 530 nm; Figure 1.11b).226 
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1.4.5. Experiments for determining the ability to relieve metal-protein complex 
cytotoxicity 
Cytotoxicity is typically determined by measuring cell viability in the presence of 
the metal−protein complex of interest. Cell types employed should reflect the disease of 
interest and cell viability can be determined through a variety of methods.228,229 Studies 
employed here utilize mouse and human neuroblastoma cell lines as well as primary 
neuron cultures taken from fetal wild type mice. These experiments utilize the popular 
MTT assay which monitors the production of a strongly colored formazan (λmax = ca. 
600 nm) generated by the reduction of MTT is classically believed to happen in the 
mitochondria, however, there is evidence which suggests the reduction can occur in the 
cytoplasm as well (Figure 1.12).228,230 This reduction is NADPH dependent, thus it only 
can occur in living cells.228,230 The absorbance values of treated cells are compared to 
control cells that were not exposed to metal−protein complexes or compound to 
determine the percent cell viability.228  
 
1.5. Conclusions 
Neurodegenerative diseases have been the focus of intense research recently, 
especially given their broad impact on public health. The complex and relatively 
unknown etiology of many of these illnesses and the relative lack of diagnostic and 
treatment methodologies make progress of paramount importance. It has been well 
established that metal ion dyshomeostasis and subsequent interaction between metal 
ions and proteins are two of a number of common factors in a variety of neurological 
 
Figure 1.12. Scheme of MTT reduction in living cells exploited by the MTT assay. MTT is reduced by an 
NADPH-dependent cellular reductase to produce the highly colored MTT Formazan. MTT = 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; MTT Formazan = 1-(4,5-Dimethylthiazol-2-yl)-3,5-
diphenylformazan. 
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diseases, including AD. Research efforts have striven to develop selective ligands and 
probes to target and mediate or interrupt the metal−protein interactions which are 
suggested to promote toxic protein aggregation in AD. The current understanding of the 
specific interactions between metal ions and proteins that can contribute to the onset 
and/or progression of neurodegenerative diseases has resulted in the design of 
molecules that target these potentially pathological metal−protein interactions. Several 
of these frameworks have shown initial promise as chemical tools to provide insights 
into the relationship between metal−protein interactions and pathogenesis in 
neurodegenerative diseases. Clarification of the link between metal ions, misfolded 
proteins, and neurodegeneration could lead to the design of compounds with more 
promising therapeutic qualities in the future. 
 
1.6. Scope of thesis 
As described above, multiple small molecules have been developed that can 
target and mediate aberrant metal−protein interactions to varying degrees. In this thesis, 
studies are carried out to better understand how small molecules interact with and 
mediate the formation of aggregates, oxidative stress, and cell death (reactivity) caused 
by the formation of metal−protein complexes. This better understanding of the activity of 
these molecules is then used to design new compounds that have different abilities to 
mediate metal-free and metal-induced abnormal protein reactivity.  
In Chapter 2, the ability to control metal−Aβ reactivity by L2-b is explored in detail 
using more in depth in vitro experiments as well as utilizing an in vivo animal model of 
AD. Building off of the promising results from Chapter 2, Chapter 3 explores the activity 
of several compounds based on the same stilbene framework as L2-b that have small 
structural differences and provides an understanding of their mode of action. Chapter 4 
utilizes the molecular level knowledge of the activity of the stilbene derivatives from 
Chapter 3 to design a series of molecules with differing activities. Additionally, in 
Appendices 1 and 2, new molecules are designed based off of a diazo form of the same 
stilbene derivative as L2-b and a 1,2,3-triazole Aβ imaging agent, respectively, and their 
abilities to mediate Aβ and metal−Aβ reactivity are evaluated.  
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Overall, the small molecules designed and studied as a part of this thesis 
demonstrate that a more complete understanding of the mode of actions behind their 
activity can allow for the development of chemical tools with targeted abilities to mediate 
metal-free protein and metal-induced protein aggregation, oxidative stress, and toxicity. 
The ability to generate a chemical toolbox of molecules that can target and modulate 
misfolded proteins and their metalated counterparts in vivo could lead to better 
comprehension of their roles in the pathogenesis of neurodegenerative diseases. This 
increased knowledge could eventually lead to the development of effective interventions 
to treat these devastating diseases.  
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Chapter 2 
A rationally designed small molecule for identifying an in vivo link between 
metal-amyloid-β complexes and the pathogenesis of Alzheimer's disease 
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2.1. Introduction 
Alzheimer's disease (AD), a progressive neurodegenerative disease, is the most 
common form of dementia afflicting 24 million people worldwide.1 Despite AD being the 
sixth leading cause of death in the United States, there are currently no disease 
modifying treatments; approved therapies only offer symptomatic relief without having 
an effect on the underlying pathogenesis.1,2 Development of effective therapeutics has 
been hindered by the fact that AD pathogenesis is still poorly understood. 
Pathologically, AD is characterized by the accumulation of aggregated, misfolded 
proteins, such as amyloid-β (Aβ) peptides (two major forms exist, Aβ40 and Aβ42).3,4 The 
amyloid cascade hypothesis suggests that Aβ is the causative agent in AD;5 however, 
the etiology of AD can be multifactorial; of particular interest is the role of Aβ with other 
factors (i.e., metals) toward AD development.4,6-11 
High concentrations of Fe, Cu, and Zn (ca. low mM) are found within Aβ deposits 
in ex vivo tissues from the AD-afflicted brain.12,13 These metal ions are observed to 
coordinate to Aβ peptides in vitro forming metal−Aβ complexes which could direct 
toxicity via two possible pathways:4,6-11,14-19 (i) metals could influence the Aβ 
aggregation pathways leading to the generation and stabilization of toxic Aβ 
oligomers;4,7-9,14 (ii) redox active metal ions [i.e., Cu(I/II) and Fe(II/III)] associated with 
Aβ are shown to produce reactive oxygen species (ROS) under physiological conditions 
through Fenton-like reactions.4,6-11,16-19 Overproduction of ROS by metal−Aβ can result 
in oxidative stress and eventually neuronal death in the AD-affected brain. Although the 
reactivity of metal−Aβ [i.e., (i) metal−Aβ aggregation (toxic Aβ oligomer formation) and 
(ii) redox active metal−Aβ-triggered ROS generation, vide supra] has been indicated in 
vitro,4,6-11,14-19 the direct involvement of metal−Aβ complexes in AD pathogenesis in vivo 
is uncertain. 
Metal chelating agents have shown that the interference of metal−Aβ interactions 
as well as the modulation of metal distribution in the brain could lead to an improvement 
in AD pathology.4,19-24 8-Hydroxyquinoline derivatives have been employed to regulate 
metal-related neurotoxicity in AD; some small molecules, including clioquinol (CQ) and 
PBT2, have indicated promising results for possible AD treatment in clinical trials.4,22,23 
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The effects of CQ and PBT2 are mainly from their ability to act as an ionophore to 
redistribute metal ions in the brain instead of directly disrupting metal−Aβ 
complexes;4,19,23-25 thus, these compounds would not be able to directly probe the 
relation between metal−Aβ complexes and AD pathogenesis. Therefore, chemical tools, 
termed as metamorphosizers, have been recently developed in order to (i) specifically 
target metal−Aβ complexes and (ii) alter the interaction between the metal and Aβ, 
consequently (iii) redirecting the toxic aggregation pathway of metal−Aβ into off-
pathway, less toxic unstructured Aβ forms and (iv) reducing metal−Aβ-induced ROS 
production, which eventually alleviates metal−Aβ-linked toxicity.4,24 
Herein, we demonstrate that a chemical tool (L2-b, Figure 2.1a) stands out as 
being well suited in vivo for identifying the association of metal−Aβ40/Aβ42 with AD 
pathogenesis, through in vitro biochemical/biophysical/cytotoxicity/metabolism 
investigations, as well as in vivo brain uptake studies. Our in vivo tool specifically 
interacts with metal−Aβ over metal-free Aβ and generates a ternary L2-b−metal−Aβ 
complex causing structural compaction, as validated by mass spectrometry (MS) and 
ion mobility-mass spectrometry (IM-MS). Most significantly, we present the first report 
that the control of metal−Aβ interaction and reactivity by an in vivo chemical tool 
mitigates amyloid pathology and improves cognitive deficits in the 5XFAD AD mouse 
model. This robust AD mouse model develops severe amyloid pathology and cognitive 
decline at an early age through high expression of three familial mutant types of human 
amyloid precursor protein (hAPP; Swedish, Florida, and London) and two mutant forms 
of presenilin (PSEN1; M146L and L286V).26 Overall, our studies establish strong 
experimental evidence for an in vivo link between metal−Aβ and AD development, 
implying that targeting metal−Aβ complexes could be an effective strategy for the future 
development of new therapeutics. 
 
2.2. Results and discussion 
 
2.2.1. Design principle and characterization of a chemical tool for investigating 
metal−Aβ complexes in vivo 
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L2-b (Figure 2.1a) was designed to target metal−Aβ complexes and modulate heir 
interaction/reactivity with subsequent reduction of toxicity,27 in order to determine 
whether they are connected with AD pathology. For in vivo applications, first, chemical 
tools for this purpose must have specificity toward metal−Aβ complexes in order to limit 
 
 
Figure 2.1. Design principle of L2-b and its effect on metal-free and metal-induced Aβ aggregation. (a) 
Design principle of L2-b, a metamorphosizer for metal–Aβ complexes: a metal binding site (orange) is 
incorporated into an Aβ interacting framework (blue). (b) Scheme showing the inhibition experiment: 
metal-free or metal-treated [CuCl2 (blue) or ZnCl2 (green)] Aβ40/Aβ42 was incubated with (+) or without (−) 
L2-b for 4 h (left) and 24 h (right). Conditions: [Aβ] = 25 µM; [Cu(II) or Zn(II)] = 25 µM; [L2-b] = 50 µM; pH 
6.6 (for Cu(II) samples) or pH 7.4 (for metal-free and Zn(II) samples); 37 °C; constant agitation. (c) 
Analysis of the size distribution of the resultant Aβ42 species by gel electrophoresis and Western blotting 
with an anti-Aβ antibody (6E10). (d) Dot blot analysis of the resulting Aβ42 species employing 6E10, an 
anti-Aβ oligomer antibody (A11), and an anti-Aβ fibril antibody (OC). (e) TEM images of the 24 h 
incubated samples (scale bar = 200 nm). 
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the disruption of other metalloproteins.4,24 This property can be imparted into small 
molecules by using inorganic chemistry concepts to allow specificity for disease-
relevant metal ions (Fe(II/III), Cu(I/II), and Zn(II)), along with limiting the metal binding 
affinity (Kd) to ≥ 10−10 M, and by including structural components for Aβ interaction.4,24 
To satisfy this aspect, L2-b (a bidentate ligand; Figure 2.1a) was constructed upon 
incorporation of two nitrogen donor atoms (for metal chelation) into the structure of an 
Aβ aggregate imaging agent (stilbene derivative; for Aβ interaction),28 which could 
interact with metal−Aβ complexes (Figure 2.1a).27 L2-b is shown to have apparent Kd 
values of ca. 10−10 and 10−6 M for Cu(II) and Zn(II), respectively, and is relatively 
selective for Cu(II) over other biologically relevant bivalent ions.27 Secondly, the 
blood−brain barrier (BBB) permeability of L2-b is critical for applications in the brain, 
which was first predicted by considering Lipinski's rules of drug-likeness and observing 
calculated logBB values.27 Employing CD1 mice, in vivo brain uptake studies of L2-b 
newly confirmed its BBB penetration. L2-b (ca. 250 ng g−1) is observed to be available 
in the brain when administered by oral gavage (10 mg kg−1) to the mice (Table 2.1). 
Thirdly, the metabolic stability of L2-b for in vivo applications was also verified utilizing 
human liver microsomes. Susceptibility of L2-b to metabolism is between 30 min and 
120 min indicating that this compound has moderate metabolic stability, suggesting its 
suitability for use in vivo. Lastly, L2-b acts as an antioxidant as well as an inhibitor of 
Cu(I/II)− or Cu(I/II)−Aβ-induced ROS production as presented in previous studies.27,29 
From our newly performed study using the Trolox equivalent antioxidant capacity in a 
cellular environment [i.e., murine neuroblastoma Neuro-2a (N2a) cell lysates],30 L2-b 
exhibits a greater free radical scavenging capacity (2.3 ± 0.2) than Trolox (1.0 ± 0.1), a 
known antioxidant vitamin E analogue. Therefore, L2-b is clearly demonstrated to be 
viable for in vivo use as a chemical tool for exploring the association of metal−Aβ 
complexes with AD pathogenesis. 
Table 2.1. Distribution of L2-b in male CD1 mice after its administration by oral gavage. 
Brain 
(ng/g) 
CSF 
(ng/mL) 
Plasma 
(ng/mL) 
Brain-to-plasma 
ratio 
253 ± 175 289 ± 126 1347 ± 671 0.19 ± 0.16 
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2.2.2. Specific modulation of metal-induced over metal-free Aβ aggregation 
pathways in vitro 
To elucidate whether L2-b could redirect metal−Aβ aggregation into off-pathway 
amorphous Aβ aggregates, suggested to be less toxic or nontoxic,31 while leaving 
metal-free Aβ cases unaffected, inhibition (Figure 2.1b) and disaggregation (Figure 
2.2a) experiments30 were performed employing Aβ40 and Aβ42, the two main Aβ forms 
found in the AD-affected brain. The influence of L2-b on both metal-free and metal-
mediated Aβ aggregation was monitored at short and long incubation time points.32 Gel 
electrophoresis and Western blotting (gel/Western blot utilizing an anti-Aβ antibody, 
6E10)30 were conducted to determine the molecular weight (MW) distribution of the 
 
Figure 2.2. Effect of L2-b on preformed aggregates of Aβ40 and Aβ42. (a) Scheme of the disaggregation 
experiment: Aβ40 (left) or Aβ42 (right) aggregates, generated by 24 h incubation of peptides with and 
without CuCl2 (blue) or ZnCl2 (green), were treated with L2-b (+) followed by an additional incubation of 4 
h or 24 h. Conditions: [Aβ] = 25 µM; [Cu(II) or Zn(II)] = 25 µM; [L2-b] = 50 µM; pH 6.6 (for CuCl2 samples) 
or pH 7.4 (for metal-free and Zn(II) samples); 37 °C; constant agitation. (b) Analysis of the size 
distribution of the resultant Aβ species by gel electrophoresis and Western blotting with an anti-Aβ 
antibody (6E10). (c) TEM images of the 24 h incubated samples (scale bar = 200 nm). 
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resulting Aβ aggregates. Dot blot analysis with an anti-Aβ oligomer antibody A1133 and 
an anti-Aβ fibril antibody OC,34 along with 6E10, was carried out to identify the type of 
Aβ species produced. Moreover, transmission electron microscopy (TEM) images were 
taken to visualize the morphologies of the resultant Aβ aggregates.30  
Both the inhibition and disaggregation experiments indicate that L2-b does not 
modulate the aggregation pathways of both Aβ40 and Aβ42 under metal-free conditions 
after either short or long incubation periods. Nearly identical MW distributions of the Aβ 
species in the absence and presence of L2-b were observed in the gel/Western blots 
(Figures 2.1c, 2.2b, and 2.3a). The dot blots of the inhibition samples indicated A11 
(oligomer)- and OC (fibril)-positive aggregates for metal-free Aβ40/Aβ42 even when
 
 
Figure 2.3. Effect of L2-b on the formation of metal-free and metal-induced Aβ40 aggregation (inhibition 
experiment). The experimental conditions are described in Figure 2.1b. (a) Analyses of the size 
distribution of the resultant Aβ40 species by gel electrophoresis and Western blotting with an anti-Aβ 
antibody (6E10). (b) Dot blot analysis of the resulting Aβ40 species employing 6E10, an anti-Aβ oligomer 
antibody (A11), and an anti-Aβ fibril antibody (OC). (c) TEM images of the 24 h incubated samples (scale 
bar = 200 nm). 
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treated with L2-b (Figure 2.1d and 2.3b). TEM images revealed that Aβ fibrils were 
mainly present in both the inhibition and disaggregation experiments of metal-free 
Aβ40/Aβ42 with and without L2-b after 24 h of incubation (Figures 2.1e, 2.2c, and 2.3c). 
Thus, metal-free Aβ aggregation is not noticeably influenced upon treatment with L2-b.
In contrast to the metal-free conditions, significantly noticeable changes in the 
metal [Cu(II) or Zn(II)]-induced Aβ40 and Aβ42 aggregation pathways by L2-b were 
observed compared to L2-b-untreated analogues. In both the inhibition and 
disaggregation experiments, after 24 h of incubation of the Cu(II)−Aβ species with L2-b, 
the resulting peptide species with a wide range of MWs were visualized by gel/Western 
blot (Figure 2.1c, 2.2b, and 2.3a). In the inhibition studies of both Aβ40 and Aβ42, as well 
as in the disaggregation experiment of Aβ42, Cu(II)−Aβ samples treated with L2-b even 
for 4 h also exhibited the distinct MW distribution of Aβ (Figures 2.1c, 2.2b, and 2.3a). 
Distinguishably, L2-b was capable of limiting the formation of A11- and OC-positive 
Cu(II)-induced Aβ40/Aβ42 aggregates at both short and longer incubation times (Figures 
2.1d and 2.3b). Morphologies of L2-b-incubated Cu(II)−Aβ, analyzed by TEM, displayed 
both narrower and shorter fibrils, as well as unstructured Aβ aggregates in the inhibition 
experiments (Figure 2.1e and 2.3c); while less dense, thinner fibrils were mainly 
observed in the disaggregation experiments (Fig. 2.2c). In the case of Zn(II)−Aβ, L2-b 
could also transform the aggregation pathways (Figure 2.1c, 2.2b, and 2.3a). The TEM 
studies revealed L2-b-triggered, smaller amorphous Zn(II)−Aβ aggregates in both the 
inhibition and disaggregation experiments (Figure 2.1e, 2.2c, and 2.3c). Overall, L2-b is 
observed to redirect metal−Aβ aggregation mainly into unstructured Aβ aggregates that 
are generated via the off-pathway aggregation and are known to be less toxic or 
nontoxic.31 Thus, L2-b could be used as a chemical tool specific for such anti-
amyloidogenic activity toward metal−Aβ complexes over metal-free Aβ in this manner. 
 
2.2.3. Formation of structurally-compact complexes with metal−Aβ not metal-free 
Aβ in vitro 
In order to explore the specific interaction of L2-b with metal−Aβ over metal-free 
Aβ, nanoelectrospray ionization-MS (nESI-MS) studies were employed (Figure 2.4a).
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When metal-free Aβ40 was allowed to react with L2-b, no binding events were observed, 
even with a six fold excess of the ligand (Figure 2.4a(ii)). In comparison, incubating a 
comparatively smaller concentration of L2-b with Aβ40 and Cu(II) promoted readily 
observed levels of complexes containing Aβ40, Cu(II), and L2-b approximately in the 
ratio 1:2:1, supporting the metal specific nature of the interaction (Figure 2.4(iv)). The 
 
 
Figure 2.4. Mass spectrometric (MS) and ion mobility-mass spectrometric (IM-MS) analyses of Aβ in the 
presence of L2-b and/or Cu(II). (a) Comparison of incubated Aβ 4+ charge states in the samples 
containing (i) Aβ40 (18 µM) alone and Aβ40 co-incubated with (ii) excess L2-b (120 µM), (iii) Cu(II) (40 µM), 
and (iv) both L2-b (40 µM) and Cu(II) (40 µM) [(v) Aβ42 (pH 9, 18 µM) with L2-b (40 µM) and Cu(II) (40 
µM) is also presented]. Consistent with data shown here, the gray signal represents a currently 
unidentified chemical modification of the N-terminus up to, and including, residue 5 (Figure 2.5) but not F4 
(Figure 2.6). The projected location of the complex consisting of Aβ42, Cu(II), and L2-b in a ratio of 1:2:1 is 
indicated in pink. (b) IM-MS analysis of Aβ40 (18 µM) incubated in the (i) absence and (ii) presence of L2-
b (40 µM) and Cu(II) (40 µM). Extracted arrival time distributions support the existence of three resolvable 
structural populations [Collision Cross Section (CCS) data, Table 2.2]. 
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formation of a ternary complex between L2-b and Cu(II)−Aβ40 is supported by the 
previously reported NMR studies of L2-b with Zn(II)−Aβ40 in solution.27 
Additionally, another MS signal was observed. This signal corresponds to an intact 
molecular mass of 89.24 Da less than the full-length Aβ40 peptide in good agreement 
with ternary Aβ40−Cu(II)−L2-b complex formation (gray, Figure 2.4a(iv)). Tandem MS 
data (Figure 2.5) and subsequent analysis of the fragment ions indicate that this new 
signal corresponds to a chemical modification within the first five residues of Aβ40 
(D1A2E3F4R5). Given a mass measurement error of ±1 Da, and supporting L2-b binding 
experiments performed using an Aβ40 F4A sequence variant, as well as acetylated 
analogs (Figure 2.6), we can eliminate alterations to F4 as a source of the product 
observed and show that free primary amines are critical for binding and subsequent Aβ 
degradation. While no direct observations of the Cu(II)−L2-b-bound Aβ42 form were 
indicated by MS, the 89.24 Da mass loss product was detected (gray, Figure 2.4a(v)) 
upon addition of both L2-b and Cu(II) to the samples, implying the generation of a 
transient ternary Aβ42−Cu(II)−L2-b complex of unknown stoichiometry. These Aβ40/Aβ42 
fragmentation results also suggest that, as expected, Cu(II) likely binds to Aβ proximal 
to the site of L2-b attachment.4,7 In all cases, neither L2-b nor Cu(II) was detected in 
complex with the identified Aβ degradation product. Detailed structures of these ternary 
complexes will be the subject of future studies. 
To study the molecular level structural dynamics by which L2-b redirects metal−Aβ 
aggregation pathways, IM-MS experiments of the complexes produced were performed.
Table 2.2. Calculated collision cross section (CCS) values* of the 4+ species of Aβ40.  
 
Species Conformation 1 (Å2) 
Conformation 2 
(Å2) 
Conformation 3 
(Å2) 
Aβ40 656.25 ± 29.01 
 720.35 ± 24.36  782.02 ± 23.86  
Aβ40 + Cu(II) 663.53 ± 26.70  728.28 ± 29.17  790.08 ± 26.96  
Aβ40 + 2Cu(II) 664.00 ± 33.33  729.18 ± 24.11  785.98 ± 33.51  
Aβ40 + 2Cu(II) + L2-b 669.26 ± 25.92  722.04 ± 23.77  794.39 ± 47.19  
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A comparison of the arrival time distributions of the metal-free Aβ40 form with the 
different ligated states supports an increasing level of structural compaction as 
additional components (i.e., Cu(II) and L2-b) associate with Aβ40 (Figure 2.4b and Table 
2.2). Analyzing the arrival time distributions for all complex states presented, along with 
the nESI-MS data, our IM-MS investigations demonstrate that L2-b is capable of 
specifically interacting with Cu(II)-bound Aβ over metal-free Aβ, subsequently promoting 
a high level of structural compaction of the complex. This binding of L2-b to metal−Aβ 
with increased structural compactness could be a key property for the distinguishable 
reorganization of metal−Aβ aggregation pathways, similar to the previously suggested 
 
Figure 2.5. Comparison of tandem MS/MS sequencing of Aβ40 (top) and the identified Cu(II)–L2-b-
dependent chemical modification product (bottom), using the quadrupole isolated 3+ charge state (trap 
collision energy 90 V). These data support that in the presence of both Cu(II) and L2-b, the Aβ amino 
acid sequence is chemically modified at a position between the primary amine on the N-terminus and R5, 
resulting in a calculated mass shift of 89.24 Da. Aβ40 F4A MS data, shown below (Fig. S4), support the 
conclusion that F4 is not the target of this modification.  Spectra depicted in black represent a 5X base 
signal magnification. 
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molecular level mode of action of EGCG toward metal−Aβ complexes which promotes 
the generation of nontoxic unstructured aggregates via off-pathway aggregation.24,31 
 
2.2.4. Targeting and reacting with metal−Aβ complexes in living cells and in the 
brain of 5XFAD AD mice 
The effect of L2-b on metal−Aβ40/Aβ42-induced toxicity was first examined using 
N2a cells, as an indication of its interaction with metal−Aβ complexes. An increase (ca. 
10−20%) in cell viability for both Aβ40 and Aβ42 was displayed upon treatment of cells 
incubated with Cu(II) or Zn(II), Aβ, and L2-b (10 µM each; Figure 2.7). Moving forward, 
the ability of L2-b to penetrate the BBB and interact with metal−Aβ species in the brain 
 
 
Figure 2.6. MS analyses of Aβ40 F4A and acetylated Aβ40 in the presence and absence of both L2-b and 
Cu(II). (a) Data for the 4+ charge states of Aβ40 F4A (18 µM) incubated with (ii) and without (i), L2-b (80 
µM) and Cu(II) (40 µM). Data support the conclusion that F4 is not required to promote the L2-b and 
Cu(II) dependent chemical modification observed (gray signal, ii). (b) Data for the 4+ charge states of 
acetylated Aβ40 (18 µM) incubated with (ii) and without (i), L2-b (80 µM) and Cu(II) (40 µM). While Cu(II) 
binding is still observed (red signals, ii), data support the conclusion that at least one Aβ40 primary amine 
is required to stabilize the interaction between Aβ40 and L2-b, as neither the bound nor chemically 
modified species is observed (pink dashed lines indicate location of the expected m/z values for bound 
states). Numerals shown above the MS peaks indicate the number of acetyl modifications detected for a 
given peak.  Mass analysis supports a range of 3 to 6 acetylated primary amines under our experimental 
conditions (of a possible 6).35 
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was verified in the 5XFAD AD mouse model. Zn(II) found in Aβ plaques was visualized 
in the brain tissue slices by a fluorophore specific for Zn(II), 6-methoxy-(8-p-
toluenesulfonamido)quinolone (TSQ; Figure 2.8).36 Administration of L2-b to 5XFAD AD 
mice intraperitoneally for three weeks on a daily basis starting at the age of three 
months resulted in drastically diminished fluorescence of TSQ in the plaques (arrows 
shown in Figure 2.8c). Additionally, in the hippocampal mossy fiber terminals, a Zn(II)-
rich region in the brain,37 there was no difference in the fluorescence of TSQ between 
wild type and 5XFAD AD mice treated daily with the vehicle, whereas L2-b reduced 
fluorescence by ca. 13% (P < 0.05) in 5XFAD AD mice over the same time span (Figure 
2.8d). Thus, these in vivo studies suggest that L2-b is BBB permeable and can enter 
the brain to interact with intracerebral metals, including those found in Aβ plaques.  
 
2.2.5. Reduction of amyloid pathology in 5XFAD AD mice 
To identify the direct involvement of metal−Aβ complexes in amyloid pathology 
leading to improved cognition, the 5XFAD mouse model of AD26 was chosen. L2-b (1 
mg kg−1) was injected into nontransgenic littermates (wild type) and 5XFAD AD mice via 
the intraperitoneal route for three weeks on a daily basis starting at the age of three 
months. All mice survived the consecutive treatments, which rarely caused changes in 
body weight (Table 2.3). Necropsy of all major organs in L2-b-treated mice revealed no 
gross changes.  
 
Figure 2.7. Influence of L2-b on the cytotoxicity of Aβ40 and Aβ42 in the absence and presence of metal 
ions. Viability of cells (%) was determined by the MTT assay in the absence (gray) and presence of CuCl2 
(blue) or ZnCl2 (green) and calculated relative to that of cells incubated only with 1% v/v DMSO. Error 
bars represent the standard deviation from three independent experiments. Conditions: [Aβ] = 10 µM; 
[Cu(II) or Zn(II)] = 10 µM; [L2-b] = 10 µM; 24 h incubation. 
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The potential association of L2-b with amyloid pathology was investigated by first 
observing the amyloid plaque load in the brain tissue of 5XFAD AD mice. When the 
brain tissue slices of L2-b-administered 5XFAD AD mice were stained with an APP/Aβ 
specific antibody (4G8) or a compact core amyloid plaque indicator (Congo red), it was 
found that the amyloid plaque burden was ameliorated (Figure 2.9). Reduction (ca. 
15%) of both the area of 4G8-immunoreactive deposits and the number of congophilic 
amyloid plaques was revealed in the cortex of L2-b-treated 5XFAD AD mice when 
compared to vehicle-treated 5XFAD AD mice (Figure 2.9c, f). The changes in the 
amount of both Aβ40 and Aβ42 in the brain tissues of 5XFAD AD mice following L2-b 
administration were also assessed. Total amounts of Aβ peptides were analyzed by an 
enzyme-linked immunosorbent assay (ELISA) in sodium dodecyl sulfate (SDS)- and 
formic acid (FA)-soluble brain tissue lysates (Figure 2.9a, b and 2.10), as well as 
oligomeric and fibrillar Aβ aggregates in the phosphate buffered saline (PBS)-soluble 
fraction (Figure 2.10c, d).38 Relative to vehicle-treated 5XFAD mice, the L2-b-treated 
5XFAD mice showed diminished cerebral levels of both Aβ40 and Aβ42 in all fractions 
 
 
Figure 2.8. Levels of Zn(II) in the brain tissues of nontransgenic wild type (WT) and 5XFAD transgenic 
mice. Amounts of Zn(II) were determined using a fluorescent dye, 6-methoxy-(8-p-
toluenesulfonamido)quinoline (TSQ), in the mossy fiber region (mf) of brains from (a) WT and (b and c) 
5XFAD transgenic mice after intraperitoneal administration of (a and b) the vehicle or (c) L2-b (1 mg per 
kg per day) for three weeks beginning at three months of age (scale bar = 100 µm). The fluorescence 
response of TSQ was also shown in the zone of amyloid plaques in 5XFAD mice (shown by arrows; b 
and c). CC, corpus callosum; CA, cornu amonis; dg, dentate gyrus. (d) The fluorescence intensity of TSQ 
was quantified in the mossy fiber region (mf in a–c) of vehicle-treated WT (black bar; n = 6) and 5XFAD 
male mice (white bar; n = 10), or L2-b-treated 5XFAD male mice (gray bar; n = 9), where the 
measurement was performed using five sagittal sections selected randomly from each animal and 
denoted as an arbitrary unit of the TSQ fluorescence [mean ± standard error of the mean (S.E.M)]. *P < 
0.05 by one-way analysis of variance (ANOVA). 
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Table 2.3. Changes in body weight in nontransgenic littermates and 5XFAD mice during the period of 
vehicle or L2-b treatment. 
 
 Wild type (WT) 5XFAD 5XFAD 
Treatment Vehicle Vehicle L2-b 
Number of animals 6 15 16 
Day Body weight (g) on day of treatment* 
1 21.3 ± 0.5 20.5 ± 0.6 20.8 ± 0.4 
2 21.8 ± 0.5 20.3 ± 0.6 20.9 ± 0.4 
3 21.3 ± 0.6 20.3 ± 0.5 20.6 ± 0.4 
7 21.2 ± 0.7 20.4 ± 0.5 20.5 ± 0.5 
14 21.3 ± 0.8 20.6 ± 0.5 20.6 ± 0.5 
21 22.2 ± 0.7 21.1 ± 0.4 21.1 ± 0.5 
mean ± S.E.M. 
 
 
 
Figure 2.9. Effect of daily treatments with L2-b for three weeks on the amyloid deposits in the brains of 
5XFAD male mice. Representative microscopic images of (a and b) 4G8-immunostained or (d and e) 
Congo red stained brain sections of 5XFAD mice, which were given daily (a and d) the vehicle or (b and 
e) L2-b (1 mg per kg per day) via intraperitoneal injection for three weeks starting at three months of age 
(magnification = 40×; scale bar = 100 µm). Inset in (d) and (e): enlarged micrographs of congophilic 
amyloid plaques in the cortical area (magnification, 400×; hip, hippocampus; ctx, cortex). To evaluate the 
amyloid pathology of the vehicle (black bars; n = 5)- or L2-b (gray bars; n = 7)-treated male 5XFAD mice, 
(c) the load of 4G8-immunoreactive amyloid deposits and (f) the number of congophilic amyloid plaques 
in the cortex were measured in five brain sections taken from each animal. *P < 0.05 by one-way ANOVA. 
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 (ca. 15−20%, P < 0.05, Figure 10a, b). Oligomeric and fibrillar Aβ species in the PBS 
fraction were additionally abated by 27% and 15%, respectively (P < 0.05, Figure 2.10c, 
d). Similarly, the overall reduction of Aβ species was also indicated by gel/Western blot, 
where Aβ monomers and oligomers were noticeably decreased in brain tissue lysates 
from L2-b-treated 5XFAD AD mice (Figure 2.10e). Together, these studies demonstrate 
that daily administration of L2-b to the AD model mitigates amyloid pathology in AD, 
including the load of amyloid plaque deposits and the levels of a wide range of 
conformations from monomers to fibrils. 
 
2.2.6. Cognitive improvement in 5XFAD AD mice 
Investigation of behavioral performance was carried out by administering L2-b to 
5XFAD AD mice which suffer from deficits in learning and memory capabilities as 
amyloid pathology progresses.26 The Morris water maze was used to evaluate different 
 
Figure 2.10. Levels of Aβ in whole brain tissues of three-month-old male 5XFAD mice. The amounts of 
(a) total Aβ40, (b) total Aβ42, (c) PBS-soluble Aβ oligomers, and (d) Aβ fibrils were assessed using ELISA 
after three weeks of treatment with vehicle (black bars; n = 5) or L2-b (1 mg per kg per day; gray bars; n 
= 7). Bars denote the levels of Aβ, which were calculated from three independent experiments and 
expressed as values per gram of tissue. *P < 0.05 or **P < 0.01 by one-way ANOVA. (e) 4–20% (lower 
panels) and 16.5% (upper panels) tris-glycine gel/Western blot analyses were performed to visualize the 
Aβ monomers and aggregates, respectively, in the brain tissue lysates of wild type (WT; left panels) and 
5XFAD male mice (right panels).  
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aspects of spatial learning and memory in three-month-old 5XFAD AD mice.26 The wild 
type mice, which were consecutively injected with vehicle during the experimental 
period, normally took shorter times upon repetition of the training trial to find the escape 
platform, located in the northwest (NW) quadrant (Figure 2.11a and b). In contrast, 
vehicle-treated 5XFAD AD mice spent longer times searching for and reaching the 
platform indicating they had difficulties with learning and memory (Figure 2.11).  
Administration of L2-b to 5XFAD AD mice led to a remarkable improvement in the 
performance of the task. L2-b-treated 5XFAD AD mice were capable of finding the 
target in a comparable time to the wild type mice displaying significantly better memory 
and learning abilities than their untreated 5XFAD AD littermates (P < 0.05, Figure 2.11a, 
b). Additionally, L2-b-treated 5XFAD AD mice took a more direct and easier path than 
the vehicle-treated 5XFAD AD mice to search for the platform (P < 0.05, Figure 2.11c). 
Therefore, L2-b, a chemical reagent specific for metal−Aβ, ameliorates cognitive 
defects in the AD mouse model, along with the attenuation of amyloid pathology. These 
 
Figure 2.11. Learning and memory abilities of three-month-old male wild type (WT) and 5XFAD male 
mice treated with vehicle (black and white bars) and L2-b (gray), measured using the Morris water maze 
task. (a) The escape latency time was counted every day during the period of the 21st–25th daily 
treatments of either vehicle or L2-b and the probe trials were performed on the day of the final 25th 
treatment to measure (b) how quickly the mice reach and (c) how long they spend in the target quadrant 
(NW, highlighted in gray; circles show images of the representative tracks of the mice in the water maze). 
*P < 0.05 or **P < 0.01 by one-way ANOVA (n = 6, 13, and 14 for vehicle-treated WT and vehicle-/L2-b-
treated 5XFAD mice, respectively). 
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overall in vivo observations and results indicate that metal−Aβ complexes could be 
directly linked to AD pathogenesis.  
 
2.3. Conclusions 
In summary, for the first time, experimental evidence affirms that metal−Aβ 
complexes can be directly associated with AD pathogenesis, by applying the first in vivo 
chemical tool which specifically targets metal−Aβ complexes and ameliorates metal−Aβ 
reactivity (i.e., metal−Aβ aggregation, formation of toxic oligomers, and ROS production) 
in 5XFAD AD mice. Our findings presented herein demonstrate the feasibility of 
developing small molecules as in vivo chemical tools for studying metal−Aβ. In addition, 
our studies indicate that research efforts toward understanding metal−Aβ-induced 
pathological pathways and identifying interrelated partners with metal−Aβ in AD onset 
and progression at the molecular level should continue to be made. The current and 
future outcomes, obtained from metal−Aβ-involved AD research, can open new 
directions for our long-term goal, the discovery of effective drugs for this fatal 
neurological disorder.  
 
2.4. Experimental section 
 
2.4.1. Materials and methods  
All reagents were purchased from commercial suppliers and used as received 
unless otherwise noted. Aβ40 and Aβ42 (the sequence of Aβ42: DAEFRHDSG-
YEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were purchased from Anaspec Inc. 
(Fremont, CA, USA). Compound L2-b was prepared using the previously reported 
procedures.27 Trace metals were removed from buffers and solutions used in Aβ 
experiments (vide infra) by treating with Chelex overnight (Sigma-Aldrich, St. Louis, MO, 
USA). Optical spectra for the measurement of Aβ concentrations were recorded on an 
Agilent 8453 UV-visible (UV-vis) spectrophotometer. Absorbance values for biological 
assays, including cell viability and antioxidant assays, were measured on a Molecular 
Devices SpectraMax 190 microplate reader (Sunnyvale, CA, USA). 
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2.4.2. Aβ aggregation experiments  
Aβ experiments were performed according to previously published methods.27,29-
31,39 Prior to experiments, Aβ40 or Aβ42 was dissolved in ammonium hydroxide (NH4OH; 
1% v/v, aq). The resulting solution was aliquoted, lyophilized overnight, and stored at 
−80 °C. A stock solution of Aβ was then prepared by dissolving lyophilized peptide in 
1% NH4OH (10 µL) and diluting with ddH2O. The concentration of the solution was 
determined by measuring the absorbance of the solution at 280 nm (ε = 1450 M–1cm–1 
for Aβ40; ε = 1490 M–1cm–1 for Aβ42). The peptide stock solution was diluted to a final 
concentration of 25 µM in Chelex-treated buffered solution containing HEPES (20 µM, 
pH 6.6 for Cu(II) samples; pH 7.4 for metal-free and Zn(II) samples) and NaCl (150 µM). 
For the inhibition studies, L2-b (final concentration 50 µM, 1% v/v DMSO) was added to 
the sample of Aβ (25 µM) in the absence and presence of a metal chloride salt (CuCl2 
or ZnCl2; 25 µM) followed by incubation at 37 °C with constant agitation for 4 or 24 h. 
For the disaggregation studies, Aβ with and without a metal chloride salt was incubated 
for 24 h at 37 °C with constant agitation to generate preformed Aβ aggregates. The 
resulting samples were then treated with L2-b (50 µM) and incubated with constant 
agitation for additional 4 or 24 h. 
 
2.4.3. Gel electrophoresis and Western blotting  
The samples from the inhibition and disaggregation experiments were analyzed by 
gel electrophoresis followed by Western blotting using an anti-Aβ antibody (6E10) 
following previously established procedures.27,29-31,39 Samples (10 µL) were separated 
on a 10-20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). Following separation, 
the proteins were transferred onto nitrocellulose membranes and blocked with bovine 
serum albumin (BSA, 3% w/v, Sigma-Aldrich, St. Louis, MO, USA) in Tris-buffered 
saline (TBS) containing 0.1% Tween-20 (TBS-T) for 2 h at room temperature or 
overnight at 4 °C. The membranes were incubated with an anti-Aβ antibody (6E10, 
1:2000, Covance, Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) for 4 h at 
room temperature or overnight at 4 °C. After washing with TBS-T (3x, 10 min), a 
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horseradish peroxidase-conjugated goat antimouse secondary antibody (1:5000 in 2% 
BSA w/v in TBS-T; Cayman Chemical Company, Ann Arbor, MI, USA) was added for 1 
h at room temperature. The ThermoScientific SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL, USA) was used to visualize protein bands. 
 
2.4.4. Dot blot analysis  
Dot blots were performed following previously established procedures with slight 
modifications.33 These experiments were prepared by placing 2.5 µL of the samples 
from inhibition and disaggregation experiments on nitrocellulose membranes. The 
samples were allowed to dry and then blocked overnight at 4 °C in 3% BSA w/v in TBS 
containing 0.01% Tween-20 (dilute TBS-T). The membranes were then incubated with 
either an anti-Aβ antibody (6E10, 1:2000), an anti-Aβ oligomer antibody (A11, 1:5000 in 
2% BSA w/v in dilute TBS-T; Invitrogen), or an anti-Aβ fibril antibody (OC, 1:5000 in 2% 
BSA w/v in dilute TBS-T; Millipore, Temecula, CA, USA) for 2 h at 4 °C followed by 
washing with dilute TBS-T (3x, 7 min). The addition of a horseradish peroxidase-
conjugated goat antimouse secondary antibody for 6E10-treated membranes or a 
horseradish peroxidase-conjugated antirabbit secondary antibody (1:10000 in 2% BSA 
w/v in dilute TBS-T; Promega, Madison, WI, USA) for A11- and OC-treated membranes 
was subsequently followed. After incubating with the secondary antibody for 1 h at 4 °C, 
the membranes were washed with dilute TBS-T (3x, 7 min). The Biosesang ECL Plus kit 
(Biosesang, Gyeonggi-do, Korea) was used to visualize the results on a ChemiDoc MP 
Imaging System (Bio-Rad, Hercules, CA, USA). 
 
2.4.5. Transmission electron microscopy (TEM)  
Samples for TEM were prepared according to a previously reported method using 
glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, 
Hatfield, PA, USA).27,29-31,39 Images from each sample were taken on a JEM-2100 
Transmission Electron Microscope (JEOL Ltd., Tokyo, Japan). 
 
2.4.6. Ion mobility–mass spectrometry (IM–MS)  
All IM-MS experiments were carried out on a Synapt G2 (Waters, Milford, MA).40,41 
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Samples were ionized using a nano-electrospray source operated in positive ion mode. 
MS instrumentation was operated at a backing pressure of 2.7 mbar and sample cone 
voltage of 40 V. Aliquots of Aβ peptides (final concentration 18 µM) were sonicated for 
10 sec prior to preincubation with, or without, a source of Cu(II) (copper(II) acetate) at 
37 °C for 10 min. After preincubation, samples were treated with or without L2-b at 
37 °C for 50 min prior to analysis. Solution conditions were 100 mM ammonium acetate 
(pH 7.5, unless otherwise stated) with 1% v/v DMSO. Acetylation of Aβ40 peptides was 
carried out using methods described previously,35 prior to overnight dialysis into 100 
mM ammonium acetate (pH 7.5). Collision cross-section (CCS) measurements were 
externally calibrated using a database of known values in helium, using values for 
proteins that bracket the likely CCS and ion mobility values of the unknown ions.42,43 
CCS values are the mean average of a minimum of five replicates (maximum of eight), 
with errors reported as the least square analysis output for all measurements.  This 
least square analysis combines inherent calibrant error from drift tube measurements 
(3%), the calibration R2 error and two times the replicate standard deviation error.  All 
other conditions are consistent with previously published methods.30 
 
2.4.7. Cell viability measurements  
Murine neuroblastoma N2a cell line was purchased from the American Type Cell 
Collection (ATCC, Manassas, VA, USA). The cell line was maintained in media 
containing 45% Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Life Technologies, 
Grand Island, NY, USA) and 45% OPTI-MEM Reduced Serum Media (Gibco), 
supplemented with 9% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, 
GA, USA), 1% non-essential amino acids (NEAA), 2 mM glutamine, 100 U/mL penicillin, 
and 100 mg/mL streptomycin (Gibco). The cells were grown in a humidified atmosphere 
with 5% CO2 at 37 °C. For the MTT assay, N2a cells were seeded in a 96 well plate 
(15,000 cells per 100 µL). The cells were treated with Aβ alone (10 µM), [Aβ + L2-b (10 
µM, 1% v/v final DMSO concentration)], [Aβ + CuCl2 or ZnCl2 (10 µM)], or [Aβ + CuCl2 
or ZnCl2 + L2-b]. The N2a cells were also incubated with a metal chloride salt (CuCl2 or 
ZnCl2; 10 µM), L2-b (10 µM), or metal/L2-b (1:1 metal:ligand ratio). After 24 h 
incubation, 25 µL of MTT (Sigma-Aldrich; 5 mg/mL in PBS, pH 7.4; Gibco) was added to 
  61 
each well, and the plate was incubated for 4 h at 37 °C. Formazan produced by the cells 
was solubilized by addition of an acidic solution of N,N-dimethylformamide (50% v/v) 
and sodium dodecyl sulfate (SDS; 20% w/v, aq) overnight at room temperature in the 
dark. The absorbance was measured at 600 nm by a microplate reader. Cell viability 
was calculated relative to that of cells containing an equivalent amount of DMSO. Error 
bars were calculated as standard errors from three independent experiments. 
 
2.4.8. Antioxidant assay  
The antioxidant activity of L2-b was determined by the Trolox equivalent 
antioxidant capacity (TEAC) assay employing cell lysates following the protocol of an 
antioxidant assay kit purchased from Cayman Chemical Company with modifications 
employing the N2a cell line.29 Cells were seeded in a 6 well plate and grown to 
approximately 80-90% confluence. Cell lysates were prepared following the previously 
reported method with modifications.44 N2a cells were washed once with cold PBS (pH 
7.4; Gibco) and harvested by gently pipetting off adherent cells with cold PBS. The cell 
pellet was generated by centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was 
sonicated on ice (5x for 5 sec pulses with 20 sec intervals between each pulse) in 2 mL 
of cold assay buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% NaCl and 0.1% 
glucose). The cell lysates were centrifuged at 5,000 x g for 10 min at 4 °C. The 
supernatant was removed and stored on ice until use. 10 µL of the supernatant was 
delivered followed by addition of compound, metmyoglobin, 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid (ABTS), and H2O2 in the specified order to 
sample wells on a 96 well plate. After 5 min incubation at room temperature on a shaker, 
absorbance values at 750 nm were recorded. The percent inhibition was calculated 
according using the measured absorbance [% inhibition = (A0 − A)/A0, where A0 is the 
absorbance of the supernatant of cell lysates] and was plotted as a function of 
compound concentration. The TEAC value of ligands was calculated as a ratio of the 
slope of the standard curve of the compound to that of Trolox (Sigma-Aldrich; Trolox = 
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; dissolved in DMSO). Duplicate 
measurements were conducted in three different experiments. 
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2.4.9. Brain uptake studies  
Brain uptake experiments were carried out using male CD1 mice (purchased from 
Vital River Laboratory Animal Technology Co. Ltd., Beijing, China) by Contract 
Research Organization, Shanghai ChemPartner Co., Ltd. (Shanghai, China). The 
studies reported here adhere to the principles of the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) International. L2-b (10 mg kg-1, 
single dose in sterile water) was administrated to mice by oral gavage. At 30 min 
postdose (n = 3 at each time point), 150 µL of blood was withdrawn via retro orbital 
puncture or cardiac puncture and transferred into tubes with spray-coated K2EDTA as 
an anticoagulant. Blood samples were put on ice and centrifuged to obtain plasma 
samples (2000 g, 5 min, 4 °C). Immediately following blood collection, mice were 
euthanized by pure CO2 inhalation. The whole brain was collected, rinsed with cold 
saline, dried on filter paper, and weighed. The brain samples were immediately 
homogenized with three volumes (v/w) of homogenizing solution (PBS). Both plasma 
and brain samples were added with an internal standard (propranolol) in acetonitrile 
(CH3CN; protein precipitation). The mixture was vortexed for 2 min and centrifuged at 
14,000 rpm for 5 min and an aliquot of the supernatant was analyzed for concentration 
of L2-b by LC-MS/MS (UPLC/MS-MS API-5500, Framingham, MA, USA), with the 
analytical lower limit of quantitation (LLOQ) values for L2-b at 2 ng/mL (plasma), 8 
ng/mL (brain), and 30 ng/mL (CSF). The supernatant was stored at −80 °C prior to 
analysis. 
 
2.4.10. Metabolic stability  
The susceptibility of L2-b to metabolism was determined by a Contract Research 
Organization (Shaghai ChemPartner Co., Ltd) using L2-b (1 mM) and ketanserin (1 
mM; as a reference) in human liver microsomes (0.75 mg/ml) for 0 min, 5 min, 15 min, 
30 min, 45 min, 60 min, 75 min, 90 min, and 120 min. The reaction mixtures also 
contained potassium phosphate buffer (100 mM, pH 7.4) and reduced nicotinamide 
adenine dinucleotide phosphate (NADPH; 6 mM). Metabolic reactions were initiated by 
the addition of NADPH and stopped at designated time points by the addition of CH3CN 
(135 µL). Precipitate was removed by centrifugation. Supernatant (50 µL) was 
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transferred to a 96 well plate containing 50 µL of millipore water for LC/MS analysis. 
 
2.4.11. Animals and drug administration  
Animal studies using male 5XFAD AD model mice were performed in accordance 
with the Guidelines for Laboratory Animal Care and Use of the Asan Institute for Life 
Sciences, Asan Medical Center (Seoul, Korea), where they were given free access to 
chow and drinking water under a 12 h light/dark cycle. 5XFAD transgenic mice 
overexpress mutant human APP695 [K670N/M671L (Swedish), I716V (Florida), and 
V717I (London)] and PSEN1 (M146L and L286V); thus, the mice rapidly develop 
pathological features of AD, such as intraneuronal and extracellular Aβ deposition, 
neurodegeneration, and behavioral disabilities.26 In this study, each mouse was given 
an injection with freshly prepared vehicle (1% v/v DMSO in 20 mM HEPES, pH 7.4, 150 
mM NaCl) or L2-b (1 mg kg-1 of body weight) into the lower right or left quadrant of their 
abdomen every day for three weeks using Ultra-FineTM II insulin syringes (Becton 
Dickinson, Franklin Lakes, NJ, USA). The body weight of the animal was measured 
immediately before the injection. Three hours after the final injection, the mice were 
sacrificed under deep anesthesia. A necropsy was performed to evaluate if there was 
drug-induced damage and the brain tissues were quickly collected and frozen with liquid 
nitrogen and stored at ‒80°C. 
 
2.4.12. Tissue preparation  
The right brain hemisphere of the mice was quickly frozen with liquid nitrogen for 
biochemical analyses. The left hemispheres were sagittally dissected at the thickness of 
12 µm on a cryostat (HM550; Microm, Walldorf, Germany), mounted onto 1% poly-L-
lysine-coated glass slides, and thereafter used for histological evaluations. 
 
2.4.13. Measurement of synaptic Zn(II)  
Freshly prepared brain sections (12 µm thickness) were stained with N-(6-
methoxy-8-quinolyl)-p-toluenesulfonamide (TSQ; 4.5 µM, Invitrogen) in 100 µL of 140 
mM sodium barbital/sodium acetate buffer (pH 10.0) for 90 sec.37 After rinsing briefly in 
physiological saline (0.9% NaCl, pH 7.2), fluorescence of TSQ on the sections was 
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photographed under a fluorescence microscope (Eclipse 80i, Nikon) with a 100X Plan 
Fluor lens and a UV-2A filter (dichroic, 400 nm; excitation, 330-380 nm; barrier, 420 nm; 
Nikon) using a digital camera (DS-Fi1/DS-U2; Nikon) and computer-assisted imaging 
software (NIS-Elements F; Nikon). The mean fluorescence intensity of TSQ in the 
mossy fiber area was measured using a computer-assisted image analysis program 
(Image-Pro Plus; Media Cybernetics, Silver Spring, MD, USA) and the level of synaptic 
Zn(II) was determined by subtracting background fluorescence as obtained at an area 
outside of the tissue section. 
 
2.4.14. Aβ40/Aβ42 quantification 
The amounts of Aβ40/Aβ42 were measured in the brain according to the methods as 
described previously.38 Briefly, the protein homogenate fractions were collected in PBS 
(pH 7.4) containing Complete™ Protease Inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany), in 2% SDS (aq), and then in 70% formic acid (FA) by serial 
centrifugations. The EC buffer-diluted protein fractions were subjected to ELISA using 
the human Aβ40/Aβ42 ELISA kit (Invitrogen), where FA-fractions were neutralized with 1 
M Tris (pH 11.0) prior to the dilution. In addition, the amounts of the aggregated or 
oligomeric Aβ in PBS fractions were also measured using Aβ Oligomers ELISA kit 
(82E1-specific; IBL International, Hamburg, Germany). The colorimetric 
quantifications were determined at 450 nm with the Synergy H1 Hybrid microplate 
reader (BioTek, Winooski, VT, USA), and the cerebral Aβ40/Aβ42 amount was calculated 
as moles per gram of wet brain tissue. 
 
2.4.15. Quantification of Aβ deposition  
In order to evaluate the development of extracellular Aβ deposits, 
immunohistochemistry studies were performed on the sagittal brain sections using an 
anti-human Aβ(17-24) antibody (4G8, 1:1000; Covance, Princeton, NJ, USA). After 
being immunologically reacted with 4G8 and biotynylated anti-mouse secondary 
antibody (Vector Laboratories, Burlingame, CA, USA), the tissue sections were 
developed in PBS containing 0.015% diaminobenzidine and 0.001% H2O2 (Vector 
Laboratories) and then examined or photographed under a light microscope (Eclipse 
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80i; Nikon, Tokyo, Japan). Next, the congophillic amyloid plaques were detected by 
staining the tissues with Accustain® Congo Red amyloid staining solution (Sigma-
Aldrich, St. Louis, MO, USA). The loads of amyloid deposits in the cortex were given as 
the percent area of 4G8-immunoreactive deposits or the number of congophilic plaques 
per mm2 of cortex area. 
 
2.4.16. Immunoblot analysis of Aβ  
Immediately after the brains were collected from the mice, the tissue lysates were 
prepared in PBS (pH 7.4) containing CompleteTM Protease Inhibitor Cocktail (Roche 
Diagnostics) and stored in liquid nitrogen. The protein amount was measured using a 
bicinchoninic acid assay (Bio-Rad). Boiled proteins were separated with the sample 
buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue, 5% 
mercaptoethanol, and 50 mM dithiothreitol) on 4-20% or 16.5% Precise Tris-Glycine Gel 
(Thermo Fisher Scientific, Rockford, IL, USA) and then transferred onto polyvinylidene 
difluoride membranes (Merck Millipore, Billerica, MA, USA) using semidry blotters 
(TE70 PWR; Amersham Biosciences, Uppsala, Sweden). After blocking in TBS-T buffer 
with 5% skimmed milk and 1% BSA (Bovostar; Bovogen, Melbourne, Australia), the 
blots were reacted with an anti-Aβ antibody (6E10, 1:1000; Covance) and then with 
horseradish peroxidase-conjugated secondary antibody (1:5000). Immunoreactive 
proteins were detected using Immobilon Western Chemiluminescent HRP Substrate 
(Merck Millipore) on the Davinch-Chemi® Chemiluminescence Imaging System (CAS-
400SM; CoreBio, Seoul, Korea). 
 
2.4.17. Behavioral evaluation  
Spatial learning and memory abilities were assessed using the Morris water maze 
task, which was composed of a cylindrical platform (15 cm in diameter) submerged 0.5 
cm below the surface of opaque water at the center of a target quadrant in the circular 
pool. The mice were subjected to three training trials per day to swim and locate the 
hidden platform for a maximum of 60 sec. The task was conducted at 3 h after each 
drug injection over a period of five consecutive days starting on the day of the 21st 
injection, during which vehicle or L2-b was still administered. The time and swimming 
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track taken to reach the escape platform were recorded and analyzed on SMART Video 
Tracking System (Harvard Apparatus, Holliston, MA, USA). Three hours later, the mice 
entered water again to swim in the absence of the platform for 60 sec and the time 
spent in each quadrant area was collected. 
 
2.4.18. Statistics  
All values are presented as the means ± standard errors of the mean (SEMs) 
unless otherwise noted. Statistical analysis was performed using one-way analysis of 
variance (ANOVA) with Student-Newman-Keuls post hoc test, or the unpaired t-test. 
Differences with P values < 0.05 were considered significant. 
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Chapter 3 
Structural similarity of small molecules, but distinct targets and reactivities in 
amyloidogenic diseases through multiple modes of action 
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3.1. Introduction 
 Metal ion dyshomeostasis, misfolded protein aggregation, and increased oxidative 
stress have been implicated in having a central role in the pathogenesis and 
progression of neurodegenerative diseases, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and amyloid lateral sclerosis (ALS).1-8 It has been suggested 
that these factors are inter-related through the development of metal–protein complexes 
that could lead to the misfolding and stabilization of abnormal protein conformations that 
facilitate and accelerate toxic aggregate formation and lead to the production of reactive 
oxygen species (ROS) through Fenton-like chemistry by redox-active metals.1-5,9-12 
Progress in generating molecules suitable to target these metal–protein complexes as 
potential treatments or as chemical tools to study their properties has been made; 
however, most of these tools share the same structural components, lack specificity for 
particular forms of metal–protein complexes, and have not had their molecular level 
mode of action elucidated.2,13 
 To gain a better understanding of this aspect and provide new insight into tool 
development, four small molecules were designed and prepared based onto a p-
iodostilbene framework with slight differences in their structures (Figure 3.1). We report 
that despite the structural changes being relatively minor, they have different activities 
toward our model targets [i.e., amyloid-β (Aβ); the amyloidogenic peptide associated 
primarily with AD, metal ions [Cu(II) or Zn(II)], ROS, and other free radicals]. By 
employing biochemical and computational approaches, it is demonstrated that these 
compounds can target and interact with metal-free Aβ and/or complexes of metal and 
Aβ (metal−Aβ) through structure-dependent modes of action leading to the redirection of 
the aggregation route to generate off-pathway forms mediating their reactivity (i.e., toxic 
aggregate formation, and ROS generation) to varying degrees. These studies 
demonstrate that slight structural variations to one framework can govern small 
molecules’ targeted capabilities of regulating multiple pathological factors found in 
neurodegenerative diseases. 
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3.2. Results and discussion 
 
3.2.1. Rational selection of small molecules and the model peptide system  
Four derivatives (1-4) of the known amyloid-interacting framework, p-iodostilbene, 
(Figure 3.1) were selected for our studies.2,14-18 These molecules have two nitrogen 
(N,N) donor atoms for metal chelation that are provided by 2-picolylamine (1-3) or [1H-
pyrrol-2-yl]methylamine (4) groups. The structures were varied further by installing 
amine (1), morpholino (2), 3,5-dimethoxy (3), or dimethylamino (4) functionalities 
(Figure 3.1). These changes should effect the interaction with metal−Aβ with the 
differences in the metal binding site mainly varying the metal binding properties while 
the other structural changes that vary hydrogen bonding and hydrophobicity of the 
compounds should effect the interaction with Aβ. 1-4 were obtained from commercial 
sources and 1, 3, and 4 were recrystallized before use. In addition to the commercially 
obtained 1, this compound was also synthesized in two steps though the reduction of 
the nitro containing compound produced from the previously reported SNAr reaction 
between 1-fluoro-4-nitrobenzene and 2-(aminomethyl)pyridine.19,20 The product was 
then isolated as the HCl salt (85% yield; Figure 3.2). 
 
Figure 3.1. Structures of 1-4 and summary of reactivity. 1, N1-(pyridin-2-ylmethyl)benzene-1,4-diamine; 2, 
4-morpholino-N-(pyridin-2-ylmethyl)aniline; 3, 3,5-dimethoxy-N-(pyridin-2-ylmethyl)aniline; 4, N1-((1H-
pyrrol-2-yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine. 
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In addition to having well known Aβ and metal−Aβ interacting properties, many p-
iodostilbene derivatives are known to penetrate the blood-brain barrier (BBB).14-18 In 
order to assess if the structures (1-4) generated via slight variations could also be 
available in the brain, the ability to cross BBB was examined through several methods. 
First, adherence to Lipinski’s rules and calculated logBB values were confirmed (Table 
3.1). All calculated values suggest that 1-4 could be able to cross the BBB. The results 
from solution speciation studies were also considered as uncharged species can 
passively diffuse across the BBB more easily than charged species.21 Since all of the 
tested compounds were shown to be predominately neutral at physiological pH (Figure 
3.3; 1, pKa1 = 4.7(6), pKa2 = 6.0(2), ca. 80% neural ligand (L) at pH 7.4; 2, pKa1 = 4.0(8), 
pKa2 = 5.5(1), ca. 95% L at pH 7.4; 3 pKa1 = n/a, pKa2 = 5.0(8), ca. 100% L at pH 7.4; 4 
not tested vide infra), an in vitro parallel artificial membrane permeability assay 
Table 3.1. Calculated and measured BBB permeability parameters for 1-4. 
 
 Parameters 1 2 3 4 Lipinski’s rules and others 
MWa 199 269 244 215 ≤ 450 
cLogPb 1.96 1.05 1.73 1.86 ≤ 5.00 
HBAc 3 4 4 3 ≤ 10 
HBDd 3 1 1 2 ≤ 5 
PSA (Å2)e 50.9 37.9 43.4 31.1 ≤ 90 
logBBf −0.563 −0.272 −0.249 −0.047 < −1.0 poorly distributed in the brain 
−logPeg 5.0(1) 4.6(5) 4.2(8) 4.9(0) 
−logPe < 5.4 (CNS+); 
−logPe > 5.7 (CNS-) CNS + ⁄ − 
Prediction 
CNS+ CNS+ CNS+ CNS+ 
aMW, molecular weight; bclogP, calculated log of water−octanol partition coefficient.; cHBA, 
hydrogen bond acceptor; d HBD, hydrogen bond donor; e PSA, polar surface area; flogBB = 
−0.0148 × PSA + 0.152 × clogP × 0.130. gDetermined using the parallel artificial membrane 
permeability assay adapted for BBB (PAMPA-BBB). 
 
 
 
 
 
Figure 3.2. Synthesis of (a) 4-nitro-N-(pyridin-2-ylmethyl)aniline and (b) 1. 
N NH2
NO2F N HN NO2
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adapted for the BBB (PAMPA-BBB) was used to confirm BBB permeability. Permeability 
values (−logPe; Table 3.1) were obtained and when analyzed together with the 
calculated values and solution speciation studies, the PAMPA-BBB assay suggests that 
1-4 can passively diffuse across the BBB and be viable structural frameworks, even with 
structural variations, for studying the inter-relationship of multiple factors involved in the 
 
Figure 3.3. Solution speciation studies of 1-3. Variable pH titrations of (a) 1 (50 µM), (c) 2 (20 µM), or (e) 
3 (100 µM) were monitored by UV-Vis. The resulting spectra were fit to obtain (g) pKa values and plot 
(b,d,f) speciation diagrams. FL = Fraction of ligand with at the specified protonation state. Charges 
omitted for clarity. Note that 4 was not determined for solution speciation due to limited stability in solution 
(100 mM NaCl, 10 mM NaOH). 
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pathogenesis of neurodegenerative diseases in the brain.  
As the model peptide, Aβ was chosen for these studies due to its interactions with 
metal ions being relativity well studied in vitro.2,9-11,22-28 Cu(I/II), Zn(II), and Fe(II) have 
been shown to coordinate to the Aβ peptide in vitro and the formation of these metal−Aβ 
complexes can direct the aggregation pathway of Aβ to generate and/or stabilize toxic 
forms. Additionally, when Aβ binds to redox-active metal ions [i.e., Fe(II/III), Cu(I/II)], the 
production of ROS occurs though Fenton-like chemistry.2,9-11,22-28 These in vitro 
observations demonstrate a clear interrelationship between Aβ, metal ions, and
 
Figure 3.4. Effect of the compounds on metal-free and metal-induced Aβ aggregation. (a) Scheme of 
inhibition experiments: freshly prepared Aβ (25 µM) in the presence or absence of Cu(II) (blue, 25 µM) or 
Zn(II) (green, 25 µM) was mixed without (lane C) or with compounds 1-4 (50 µM, lanes 1-4) and 
incubated at 37 oC with constant agitation for 24 h. Gel/Western blot analysis of the molecular weight 
distribution of the resulting (b) Aβ40 and (c) Aβ42 species using anti-Aβ antibody (6E10). (d) Morphologies 
of the Aβ40 aggregates as observed using TEM (scale bar = 200 nm). 
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Figure 3.5. Ability of 1-4 to disrupt pre-formed metal-free and metal−Aβ aggregates. (a) Disaggregation 
experiment scheme: Metal-free and metal induced aggregates of Aβ were generated by incubating 
mixtures of freshly prepared Aβ40 or Aβ42 (25 µM) in the presence or absence of Cu(II) (blue, 25 µM) or 
Zn(II) (green, 25 µM) at 37 oC with agitation. After 24 h, samples were treated with 1-4 (50 µM) and 
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incubated for an additional 24 h. Gel electrophoresis and Western blot analysis of the molecular weight 
distribution of the resulting (b) Aβ40 and (d) Aβ42 species using anti-Aβ antibody (6E10). Morphologies of 
the (c) Aβ40 and (e) Aβ42 species as observed using TEM (scale bar = 200 nm). 
 
oxidative stress linked through metal−Aβ complexes.2,4,9,10,12,29,30 This makes Aβ good 
model system for studying the ability of small molecules to target and mediate the 
reactivity of apparent metal−amyloid interactions. 
 
3.2.2. Reactivity I: Modulation of metal-free and metal-induced peptide 
aggregation by 1-4 
 The effect of the small structural differences on the ability of 1-4 to redirect the 
aggregation of both metal-free Aβ and metal−Aβ in inhibition (Figure 3.4a) and 
disaggregation experiments (Figure 3.5a) was evaluated using gel electrophoresis
followed by Western blotting (gel/Western blot) with an anti-Aβ antibody (6E10) to 
determine the molecular weight (MW) distribution of the resulting peptide species in 
addition to observing the morphologies of the aggregates by transmission electron 
microscopy (TEM). Experiments were carried out with the two major Aβ isoforms, Aβ40 
and Aβ42, found in the brain of AD.9,31 
 First, the alteration of metal-free Aβ aggregation was studied. The compounds (1-
3) with different substituents on the phenyl ring (Figure 3.1) did not lead to noticeable 
diversion of the metal-free aggregation pathway (Figures 3.4b-d, 3.5b-e, and 3.6).
Changing the pyridine (1-3) to a pyrrole (4), however, had a pronounced influence on 
metal-free Aβ aggregation. Treatment of Aβ40 with 4 produced forms that were greater 
than 50 kDa in both inhibition and disaggregation samples, while in the case of Aβ42 
increased species ≤ 50 kDa were detected by gel/Western blots, which was more 
evident in settings of the inhibition than the disaggregation (Figures 3.4b,c and 3.5b,c). 
Additionally, in the Aβ40 inhibition and disaggregation, TEM images smaller and more 
amorphous species were observed (Figures 3.4d, 3.5c,e, and 3.6); however, these 
changes were less noticeable in the Aβ42 samples (Figures 3.5e and 3.6).  
 Next, the ability to control Cu(II)- and Zn(II)-induced aggregation was evaluated. 
Compound 1 demonstrated the capacity to redirect only Cu(II)-promoted Aβ40 and Aβ42 
aggregation (Figures 3.4b,c and 3.5b,d), even when higher Zn(II) concentrations 
